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Abstract
As our understanding of the microbial world has progressed, so too has the
backlog of information and open questions generated from the thousands of
uncharacterized proteins and metabolites with potential applications as biofuels,
therapeutics, and biomaterials. To address this problem, new tools need to be
developed in order to rapidly test and take advantage of uncharacterized proteins
and metabolites. Cell-free systems have developed into a high-throughput and
scalable tool for synthetic biology and metabolic engineering with applications
across multiple disciplines. The work presented in this dissertation leverages cellfree systems as a conduit for the exploration of protein function and metabolite
production using two complementary approaches. The first elucidates interaction
networks

associated

with

secondary

metabolite

production

using

a

computationally assisted pathway description pipeline that employs bioinformatic
searches of genome databases, structural modeling, and ligand-docking
simulations to predict the gene products most likely to be involved in a metabolic
pathway. In vitro reconstructions of the pathway are then modularly assembled
and chemically verified in Escherichia coli lysates in order to differentiate between
active and inactive pathways. The second takes a systems and synthetic biology
approach to engineer Escherichia coli extracts capable of directing flux towards
specific metabolites. Using growth and genome engineering-based methods, we
produced cell-free proteomes capable of creating unconventional metabolic states
with minimal impact on the cell in vivo. As a result of this work, we have significantly
v

expanded our ability to use cell extracts outside of their native context to solve
metabolic engineering problems and provide engineers new tools that can rapidly
explore the functions of proteins and test novel metabolic pathways.
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Chapter 1
INTRODUCTION

1

History of Cell-Free Systems
The use of cell-free systems is a relatively old set of techniques starting with
one of its first uses as a means of elucidating the incorporation of amino acids into
proteins. Various publications using a variety of extract donor cells followed and
culminated in the first use of an E. coli cell-free extract to connect nucleotide triplets
and the amino acids they encoded by Nirenberg and co-workers, ultimately leading
to the decryption of the genetic code 1–4. Though the technique was used for
decades as a small-scale protein production system, refined protocols developed
in the last 20 years significantly improved its function and generated interest in the
further development of cell-free systems5. Advances in cell-free expression, for
instance, have dramatically improved its use as a method for the expression of
membrane-bound proteins, a normally difficult task when attempted with traditional
methods. Since these early efforts, the field has begun to expand the functions of
cell-free systems, with one of the main demarcations being that of the basic
functions of the cell-free system being geared either towards peptide production in
the form of cell-free protein synthesis (CFPS) or metabolite production in the form
of cell-free metabolic engineering (CFME)5–9.
The earliest efforts in CFPS took place decades before the advent of synthetic
biology with Spirin and coworkers using a cellular extract of Escherichia coli
capable of in vitro translation from mRNA templates10. Shortly thereafter, coupled
in vitro transcription and translation was carried out from a heterologous DNA
template in the crude S30 extract of E. coli11. These early efforts led to significant
2

advances in the field of cell-free production systems with a major milestone
reached in 2001 with the publication of Ueda’s work reconstituting E. coli’s
transcription and translation machinery using entirely purified components 12.
Advances in commercial optimization and fundamental research have iterated
upon Ueda’s original design providing one of the most popular in vitro research
tools and protein production platforms13–15. Higher-order functions such as
membrane protein production and post-translational modifications, though difficult
to replicate in E. coli extracts, have been generated through the use of extracts
from more eukaryotic organisms such as wheat germ, insect, and CHO cells16–18.
Though much of the research concerning cell-free systems has focused on
protein synthesis, the robust nature of extracts has also shown them to be effective
bioproduction tools for biofuels, therapeutics, and biomaterials. The field of cellfree metabolic engineering takes advantage of the natural function of glycolysis in
the cell-free proteome to rapidly prototype metabolic pathways and to serve as a
bioproduction platform in its own right. The S30 CFPS system serves as the basis
of much of the early CFME work as simple heterologous pathways were expressed
or exogenously introduced into S30 CFPS extracts19,20. The process of coupling
glycolysis in crude lysates with external enzymes and the necessary cofactors
enabled a significant amount of control over metabolic flux compared to living
systems. Whereas regulatory mechanisms and the need to maintain cell viability
would normally impair the function of an in vivo bioproduction system, the removal
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of the cell-free proteome from the cellular context eliminates this need and permits
biosynthetic pathways to be prototyped and engineered in vitro.

Scope of Dissertation
The projects described in this thesis have been designed to facilitate the use of
cell-free systems for use in research and industry. Cell-free systems probe cellular
metabolism outside of their native context providing a more accessible
environment for measurements of biological functions. This is leveraged towards
the development of three cell-free technologies. The first is a cell agnostic method
of analyzing secondary metabolism using computational tools and cell-free
modular assembly of pathway components. The second shows the potential of
growth enabled engineering of cell-free metabolic engineering systems. The third,
develops a technique to direct flux in cell-free metabolism through the engineering
of the cell-free proteome. These advances provide the tools necessary to further
the use of cell-free systems for understanding and harnessing the value of the
microbial world.

Cell-Free Enabled Biological Discovery
Our continued study of the microbiological world has created a backlog of
information and open questions. Large collections of genomic information like the
National Center for Biotechnology Information (NCBI) house over 40M proteins
alone, the overwhelming number of which remain uncharacterized 21. The
information thus leaves thousands of potentially useful proteins and metabolites
4

uncharacterized and unused. From a scientific point of view, this limits the amount
of information we can harness when developing new studies as our current
understanding of potential proteins or products can be largely theoretical. From an
economic view, the resources required to study even a fraction of the backlog
makes the endeavor prohibitively expensive with current methods. As a result, we
are left with thousands of proteins and metabolites with potential applications as
biofuels, therapeutics, and biomaterials left without study. To address these
problems, new tools need to be developed in order to rapidly test and take
advantage of uncharacterized proteins and metabolites. To further this effort, we
are pursuing the study of cell-free systems as a conduit for the exploration of
protein function and metabolite production.
Cell-free systems have developed into a powerful tool for synthetic biology and
metabolic engineering with applications across multiple disciplines. Developments
in cell-free system technology over the last 10 years have remarkably improved its
capacity for expressing proteins as well as created the field of cell-free metabolic
engineering19,20,22,23. Our ability to use cell extracts outside of their native context
to solve metabolic engineering problems has provided an excellent opportunity to
engineer new tools that can rapidly explore the function of proteins and test new
metabolic pathways19,24. As cell-free extracts are devoid of the need to propagate,
production is limited only by the efficacy of the production system. As a result,
there are an almost limitless number of metabolites and peptides that can be
expressed using cell-free systems.
5

For the first section of this work, I have developed a scalable testing platform
for protein function25. Automated annotations while informative for high-throughput
analysis, are not a perfect substitute for empirical experiments and poor
annotations due to lack of characterization are common. The inability to confidently
predict the function of an enzyme and its place in a metabolic pathway has become
a consistent problem in the study of microbial organisms, therefore, new
technologies must be developed to quickly and accurately elaborate the function
of metabolic pathways and individual organisms. Through the production of
uncharacterized proteins using crude extracts coupled with computational tools
such as bioinformatic analysis and ligand-docking simulations, we hope to rapidly
generate and test hypotheses regarding the function of individual proteins and
complete pathways in the organism Pantoea sp. YR343.

Engineering Cell-Free Metabolism
Work performed in the laboratories of Michael Jewett and James Bowie, have
sought to develop cell-free systems into easily engineered bioproduction
platforms. In Jewett’s case, the need to prototype metabolic pathways has become
one of the driving forces behind their work 26,27. Traditional methods of generating
clones with heterologous expression plasmids are limited as the cell may not be
able to produce the metabolite of interest without suffering from toxicity 5. Cell-free
systems help resolve this problem, by expressing individual proteins in a cell-free
extract, thereby allowing for modular combinations of extracts to be tested for
production without the need for a viable expression strain. To date, the Jewett lab
6

has shown that crude-cell free extracts derived from E. coli can be used to
generate glycolytic intermediates and power the production of metabolites such as
2,3-butanediol and n-butanol19,20. The Bowie lab has taken a similar approach
towards the production, of the bioplastic polyhydroxybutyrate 28. Interestingly, they
take an approach similar to the PURE system by employing purified enzymes to
create their bioproduction system12. This approach allows them to maintain control
over cofactor recycling and balance thus eliminating the need for the cell’s
regulatory networks. Both approaches take advantage of a stable set of proteins
capable of functioning outside of the cell, but in environments with different levels
of complexity. In the case of the purified systems, attempts to make limonene, led
to a maximum productivity of ~0.1 g l-1 h-1 over a 5-day period24. Significantly higher
rates of production were seen in the case of 2,3-butanediol (11.3 g l-1 h-1) over a
period of only a few hours19. Though a direct comparison of these systems has yet
to be done, the variety of peptide components present in the crude extract and the
relatively high yields suggest the system is better optimized for bioproduction.
The second major section of this work, encompassing chapters 2 and 3, will
focus on expanding recent efforts towards developing cell-free systems capable of
generating metabolic products. Chapter 2 focuses on the investigation and
engineering of the crude E. coli cell lysates through growth condition-based
methods. This showed the use of shotgun proteomics and traditional analytical
techniques as enabling technologies for rapidly engineering cell-free systems with
an emphasis on the central metabolic precursor pyruvate.
7

Chapter 3 describes a Multiplex Automated Genomic Engineering (MAGE)enabled protocol to reduce CFME extract contents through the incorporation of
6xHis tags on peptides detrimental to pyruvate pooling. This technique generates
modified proteomes in order to produce engineered metabolic states with minimal
impact on the cell in vivo thus enabling the ability to rapidly manipulate central
metabolism without creating toxic phenotypes as often occurs from in vivo
metabolic engineering. More broadly, this work reports on novel engineering tools
capable of producing metabolic states traditionally impossible in living organisms.

Organization of Dissertation
The first chapter was originally published as the article “Computationally guided
discovery and experimental validation of Indole-3-acetic acid synthesis pathways”
and was undertaken to facilitate the annotation of uncharacterized proteins as part
of the Plant-Microbe Interfaces (PMI) Science Focus Area (SFA) at Oak Ridge
National Laboratory (ORNL)29. The second chapter is adapted from the article
“Elucidating the potential of crude cell extracts for producing pyruvate from
glucose” wherein we used metabolic proteomic analysis to measure the effect
growth conditions can have on the function of cell-free extracts30. The third chapter
“Engineering unconventional metabolism in cell-free systems” currently available
on bioRxiv and explores a method of reducing cell-free proteomes to engineer cellfree metabolism. The supplementary information for each article is included in its
respective chapter’s Appendix. References for each chapter have been
consolidated at the end of the document.
8
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Chapter 2
COMPUTATIONALLY GUIDED
DISCOVERY AND EXPERIMENTAL
VALIDATION OF INDOLE-3-ACETIC
ACID SYNTHESIS PATHWAYS

10

A version of this chapter was originally published as:
C. Garcia, D., Cheng, X., L. Land, M., F. Standaert, R., L. Morrell-Falvey, J.,
and J. Doktycz, M. (2019) Computationally Guided Discovery and Experimental
Validation of Indole-3-acetic Acid Synthesis Pathways. ACS Chem. Biol. 14,
2867–2875.

Abstract
Elucidating the interaction networks associated with secondary metabolite
production in microorganisms is an ongoing challenge made all the more daunting
by the rate at which DNA sequencing technology reveals new genes and potential
pathways. Developing the culturing methods, expression conditions, and genetic
systems needed for validating pathways in newly discovered microorganisms is
often not possible. Therefore, new tools and techniques are needed for defining
complex metabolic pathways. Here we describe an in vitro computationallyassisted pathway description approach that employs bioinformatic searches of
genome databases, protein structural modeling, and protein-ligand docking
simulations to predict the gene products most likely to be involved in a particular
secondary metabolite production pathway. This information is then used to direct
in vitro reconstructions of the pathway and subsequent confirmation of pathway
activity using crude enzyme preparations. As a test system, we elucidated the
pathway for biosynthesis of indole-3-acetic acid (IAA) in the plant-associated
microbe Pantoea sp. YR343. This organism is capable of metabolizing tryptophan
into the plant phytohormone IAA. BLAST analyses identified a likely three-step
pathway involving an aminotransferase, an indole pyruvate decarboxylase, and a
dehydrogenase. However, multiple candidate enzymes were identified at each
11

step, resulting in a large number of potential pathway reconstructions (32 different
enzyme combinations). Our approach shows the effectiveness of crude extracts to
rapidly elucidate enzymes leading to functional pathways. Results are compared
to affinity-purified enzymes for select combinations and found to yield similar
relative activities. Further, in vitro testing of the pathway reconstructions revealed
the “underground” nature of IAA metabolism in Pantoea sp. YR343 and the various
mechanisms used to produce IAA. Importantly, our experiments illustrate the
scalable integration of computational tools and cell-free enzymatic reactions to
identify and validate metabolic pathways in a broadly applicable manner.

Introduction
Metabolism is a complex network of interconnected chemical pathways
responsible for an organism’s subsistence. In addition to macromolecules, small
molecules (metabolites) are produced by cells. Primary metabolites (such as
sugars, amino acids, lipids, nucleotides, and cofactors) provide energy, serve as
building blocks for macromolecules or otherwise support core cellular functions.
These molecules are common to many organisms, and their metabolism
(biosynthesis and subsequent transformations) is relatively well understood.
Secondary metabolites are small molecules made for other purposes, such as
signaling and defense. They are highly diverse and produced by a limited number
of organisms. While our understanding of primary metabolic networks has come a
long way, the pathways by which the vast majority of secondary metabolites are
created or utilized are poorly defined. For an overwhelming number of
12

microorganisms, there is little in the way of analytical evidence that a given
pathway is either present or active31,32. This problem has expanded with the
increase in genome-scale sequencing efforts. Genetic information on millions of
proteins provide hints as to the existence of metabolic pathways, but robust
methods for deciphering and confirming the metabolic potential hidden in this
information are lacking33. Large collections of genomic data, such as the National
Center for Biotechnology Information (NCBI) database, house over 40M protein
sequences, the majority of which remain uncharacterized. 21 Automated
annotations, while informative, are often incorrect and impede facile determination
of metabolic capabilities 34,35. The inability to confidently predict the function of an
enzyme and its place in a metabolic pathway has become a consistent problem in
the study and application of metabolic processes. Therefore, new approaches are
needed for quickly and accurately elaborating the metabolic capabilities of
microorganisms.
Current methods for defining metabolic networks can be slow and labor
intensive. Given that methods for cultivation, pathway expression, and genetic
manipulation are not always possible, conventional experimental approaches to
the study of metabolic processes in newly identified microorganisms can be a
challenging endeavor36–39. Previous work has sought to remedy this problem by
leveraging computational tools to reveal the presence and potential function of a
protein40. The combined use of bioinformatic software and structural data has
resulted

in

significant

strides

in

predicting

enzymatic

functions

from
13

uncharacterized proteins41–43. For example, the addition of complementary data,
such as genomic context and ligand docking analysis, has furthered this pursuit by
demonstrating the functionality of multi-input predictions to generate testable
hypotheses44. Such efforts have continued with recent advancements such as
integrative pathway mapping wherein the function of a candidate enzyme and its
potential metabolic pathways are predicted by combining information such as
ligand docking, chemoinformatic analysis, genomic context, and chemical
screening in a single analysis45. While these efforts have advanced significantly in
recent years, determining the efficacy of these computationally-based approaches
for defining protein function and pathway connectivity still requires experimental
verification, and determination of protein activity remains a major bottleneck for
effective gene annotation and pathway analysis.
To facilitate the definition and confirmation of metabolic pathways, we sought to
develop a simple stepwise method that initially culls a large subset of proteins
related to a pathway, using in silico methods, and tests the remaining potential
pathways through scalable, in vitro biochemical experiments. Our combined
computational and empirical approach towards pathway description consists of
three steps. First, bioinformatic analyses of the genome or genome database of
interest are performed using query enzymes described in the literature in order to
find homologous enzymes and identify potentially complete pathways. In addition
to removing the overwhelming majority of the genome, this bioinformatic step has
the benefit of providing a loosely culled set of enzymes with potential activity based
14

on homology. Second, ligand-docking simulations are performed with protein
crystal structures or computationally modeled structures to further cull the listed
enzymes

to

those

most

likely

to

interact

with

their

predicted

substrates/intermediates. Third, small-scale, heterologous expression and in vitro
reactions in the crude extract are performed to examine the contribution of
individual enzymes to the predicted pathways, thus verifying pathway activity
without the need for lengthy purification efforts. The resulting new understanding
of the pathway and its component enzymes can then be used to refine gene
annotation and make high-quality predictions for the presence of the same
pathway in other organisms by clustering potential enzymes with the verified
subset.
To test the effectiveness of using computationally guided discovery coupled with
experimental validation in crude extracts, we examined the production of the
phytohormone indole-3-acetic acid (IAA) from tryptophan in Pantoea sp. YR343
(YR343), a root colonizing member of the Populus deltoides plant-root
microbiome46. This plant regulatory metabolite can be the product of a complex set
of interconnected metabolic reactions. Notably, Pantoea sp. YR343 was shown
previously to produce IAA in the presence of tryptophan, but the expected
enzymes do not exist in a common operon

47

. This lack of common genomic

context coupled with the annotation of many of the potential candidate enzymes
confounds pathway determination. Further, as with many products of secondary
metabolism, the number of potential pathways, as well as their interconnected
15

nature, complicates understanding of flux through the pathway and its potential
control mechanisms. As described below, the combined computational culling and
in-vitro verification approach effectively defines the functional capabilities of the
component enzymes and the tryptophan to IAA pathway in Pantoea sp. YR343.

Results and Discussion
Bioinformatic Analyses Indicate Complex IAA Metabolism in Pantoea sp.
YR343
Plants experience complex interactions with the microbial communities
immediately surrounding and within their root systems 48. The microbes in these
systems are composed of bacteria, fungi, and archaea capable of influencing plant
behavior through chemical signals49. Pantoea sp. YR343, a previously sequenced
member of the P. deltoides plant-root community, was found to produce the plant
phytohormone indole-3-acetic acid from tryptophan through an uncharacterized
pathway46,50. Because some intermediates are shared by these pathways, there
are seven interconnected but discrete potential pathways for IAA production from
tryptophan (Figure 2.1)47,51. Prospective IAA biosynthetic pathways in YR343
were identified following a BLAST search using 11 different enzymes associated
with these pathways acquired from bacterial and plant genomes (Appendix Table
2.1). Pantoea sp. YR343 contains at least one enzyme homolog for each of the
known IAA pathways, but the only complete route from tryptophan to IAA is the
IPA pathway, in which tryptophan is first converted to indole-3-pyruvate, then
16

indole-3-acetaldehyde, and finally IAA by an aminotransferase (Am-Trf), an indole
pyruvate decarboxylase (IPDC), and an indole acetaldehyde dehydrogenase
(IALDh), respectively (Figure 2.1, Appendix Figure 2.4). An E-value of 1e-25 was
used as a cutoff value as it removed all enzymes from the known non-IAA
producer, E. coli. Two of the three nodes in Pantoea sp. YR343’s potential IAA
pathway had multiple possible enzymes, specifically one aminotransferase, two
IPDCs, and 16 dehydrogenases. Therefore, 32 distinct enzyme combinations
could potentially complete a pathway for tryptophan to IAA conversion.

17

Figure 2.1. General metabolic model of the conversion of tryptophan to IAA. Enzymatic steps are
written above the colored arrows and names of ligands and products underneath their molecular
structure. The seven pathways found to produce IAA from tryptophan are color coded as follows:
black, indole pyruvate pathway (IPA); green, tryptamine pathway (Tryp); magenta, tryptophandependent auxin biosynthesis pathway (TDA), red, 2-step Indole-3-acetamide pathway (IAP-2);
purple, 3-step indole-3-acetamide pathway (IAP-3), yellow, four-step indole-3-acetamide pathway
(IAP-4); blue, indole-acetaldoxime/indole-3-acetonitrile pathway (NIT).

Computational screening of ligand-docking interactions
To cull the list of potential gene products and resulting enzyme combinations
possibly responsible for IAA production in Pantoea sp. YR343, ligand docking was
used as a means of testing metabolic interactions and removing enzymes that are
unlikely to bind their respective substrates/products. Given the unavailability of a
crystal structure for any of the 19 enzymes, Phyre2 was used to generate
18

homology models and predict ligand binding sites (Figure 2.2A)52. Phyre2’s topscoring model and its predicted ligand-binding site were used as the basis for
analyzing how the enzyme interacts with its potential substrate/product (Figure
2.2B,C).

Figure 2.2. Homology modeling and ligand docking to pmi39_00059 IPDC. A. Docked indole-3pyruvate in IPDC PMI39_00059. B.Docking search space (black box) and region predicted to be
binding pocket by Phyre2. C. Schematic representations of docked ligands. Residues involved in
hydrogen bonding interactions are shown as green dotted lines with the corresponding donoracceptor distance is shown as a ball and stick model. Residues involved in van der Waals
interactions with the ligand are shown with spikes.

The binding of a ligand in the binding pocket was visually inspected in n ≥ 5
independent simulations using Vina. A simple binary designation of binding or nonbinding was then used to cull enzymes from being part of the IAA conversion
pathway (Appendix Figure 2.5). Phyre2’s 3DLigandSite was used to determine
the position of the binding pocket based on 3DLigandSite’s structural library of
homologous peptides with bound ligands (Appendix Figure 2.6)53. Proteins
capable of binding the expected ligands were kept in the pool of potential enzymes
while those unable to bind were removed (Appendix Table 2.2). Consequently,
19

as the aminotransferase successfully accommodated tryptophan in its binding
pocket, it was retained. Only one of the two IPDCs was capable of binding indole3-pyruvate, and 9 of the 16 potential IALDh enzymes were predicted to bind indole3-acetaldehyde. Removing those enzymes that failed the docking step lowered the
possible pathways to nine enzyme combinations.
Pathway verification
Our first set of in vitro experiments tested each of the nine predicted IAA enzyme
combinations using heterologously expressed enzymes in clarified crude extracts
(Am-Trf + IPDC + IALDh). Testing each combination for IAA production revealed
that five of the potential enzyme sets produced IAA in relatively large amounts (>12
µg/mL) while two sets produced relatively low amounts (<3 μg/mL) and two other
combinations showed no IAA production (Figure 2.3A). As expected, the control
reactions containing just host extract derived from either BL21 Star(DE3) or
BL21(DE3)pLysS did not produce IAA. Each node in the IAA pathway was
subsequently tested by replacing it with a blank extract from BL21 Star(DE3)
(Figure 2.3B). Control reactions without a heterologously expressed Am-Trf were
performed using the most active IALDh enzymes as their production had
previously been verified. In all cases, each pathway showed IAA production in the
absence of Am-Trf.

The IAA levels produced in these control reactions are

relatively high and are likely due to the presence of aminotransferase activity in the
E. coli extract. A similar experiment was performed but without the presence of the
heterologously produced IPDC. In all cases the absence of IPDC prevented IAA
20

production, showing that IPDC is essential for IAA production in the bacterial
extract. Similarly, the presence of a heterologously produced IALDh was essential
for IAA production as in its absence no detectable IAA was produced. Of the nine
IALDhs that passed the ligand docking test, five were able to complete the IAA
pathway when combined with an Am-Trf and IPDC.
It was important to determine if the in-silico culling had eliminated viable
enzymes. Accordingly, the remaining IPDC and seven of the IALDhs removed from
the pool of enzymes during the ligand-docking analysis were similarly cloned,
expressed, and tested for a potential role in IAA production. When combined with
verified IALDhs, the culled IPDC, IPDC2, showed low IAA production, while two of
the seven potential IALDhs were found to produce IAA at levels comparable to
those of the non-culled enzymes (Figure 2.3C). The IALDh reactions showed that
ligand docking had a false negative rate of 28.6%, substantially lower than the
false positive rate of 44.4%.
In order to determine the advantages and effectiveness of using crude extract
preparations for pathway validation, enzymes with positive activity results in crude
extracts were affinity purified using 6xHis tags. From the potential 10 enzymes, 5
were successfully affinity purified and used for IAA production experiments.
Enzymatic combinations were prepared using AMTRF1, IPDC1, IPDC2, IALDH7,
and IALDH16 (Appendix Figure 2.7). The purified protein reactions showed the
same activity trends as those that employed using crude extract combinations.
Specifically, the absence of IPDC1 was shown to be necessary for IAA production
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as its absence halted IAA production. IALDH16 maintained its relatively high-rate
of activity as reactions containing IALDH16 produced 5.66 μg/mL IAA compared
to the IALDH7’s 2.04 μg/mL. The aminotransferase (AMTRF1) was able to carry
out the expected transamination, though only ~1 μg/mL of IAA was produced
(Appendix Figure 2.8).
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Figure 2.3. Modular assembly of potential IAA producing pathways. Complete pathways were
obtained by using a single protein from each enzymatic step and measuring the terminal production
of IAA. Gene loci are listed in Appendix Table 2.2. A. Only enzymes found to be bioinformatically
related to a verified IAA enzyme and capable of docking their respective ligand was used to
measure the initial concentration of IAA. Each reaction included a single aminotransferase, a single
IPDC, and a single IALDh. B. Control reactions were performed to show the importance of individual
metabolic steps. BL21 corresponds to an extract replaced with a BL21 Star DE3 extract containing
no heterologously expressed protein. C. Culled enzymes were tested for activity to determine the
rate of false negatives from Vina.
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The plant microbiome consists of a complex network of chemical
communications between a host and its microbial colonizers. IAA metabolism is
highly relevant to plant-microbe interactions and serves as an important test case
in developing a deeper understanding of both cellular metabolism and microbial
communities. Even an apparently simple, three-step secondary metabolic pathway
can lead to a large number of potential enzyme candidates and combinations that
traditional methods cannot easily decipher. This work aims to refine an approach
that can define relevant metabolic pathways, thus decreasing the resources
necessary to establish secondary metabolic pathways.
An initial model for potential IAA metabolic pathways was created from the
literature to generate BLAST hits. A relatively small set of enzymes involved in the
known IAA pathways generated a large list of potential IAA pathway components
in Pantoea sp. YR343. But, the comparison of potential pathway models and
BLAST results provided a valuable culling step as it effectively removed enzymes
from the querying pool and left the IPA pathway as the most likely generator of
IAA. Further, BLAST analyses were key for IAA pathway description due to the
lack of genomic context. Notably, of the nine enzymes that were eventually verified
to be active in Pantoea sp. YR343’s IAA metabolism, only three were found to exist
within potential operons, all of which were unrelated to IAA metabolism (Appendix
Figure 2.5).
In an effort to further cull the list of potential pathway components, homology
modeling and ligand docking were employed. These emerging computational tools
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can test a large set of potential candidates by virtue of the candidate’s homology
to the query set or ability to bind the predicted ligand. This study leverages previous
efforts showing that the combined use of computational methods such as BLAST,
homology modeling and ligand docking, while generating false positives and false
negatives, is capable of identifying active proteins 54,55. In this work, we used a
readily accessible program, Vina, to dock ligands to the binding pockets of the
protein homology models predicted by Phyre2 and 3DLigandSite. This process
can be applied easily to a large number of candidate proteins and lends itself to
further optimization and large-scale automation. As with many types of predictive
analysis, binding affinity calculations are only estimates and may yield errors. Of
the 19 proteins that passed the ligand docking test, seven were verified as having
relevant substrate activity. Our analysis of each protein removed from the pool of
enzymes during the ligand-docking step showed that of eight culled enzymes
tested using Am-Trf1 and IPDC1, two of the culled IALDhs were found to produce
IAA at levels comparable to those of the enzymes originally selected based on the
ligand-docking (Figure 2.3C). Overall, the presence of false negatives and
positives is expected in this form of analysis and our results favor well when
compared to similar studies56. Notably, less stringent conditions are capable of
removing many false negatives by using higher energy confirmations, but this
practice may exacerbate the acquisition of false positives57,58. While these
accessible structural modeling and ligand docking tools can reduce search space
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and simplify downstream in vitro experiments, further refinements are needed
before confidently employing these tools on more complex pathways.
Future efforts to improve the performance of docking and homology modeling
could lean more on an ensemble-based docking strategy akin to the Similarity
Ensemble Approach (SEA), in which the binding ability is evaluated by a set of
ligands (e.g., ligands similar to the target substrate/product and transition state
structures), to obtain a more robust prediction of enzyme function59. Moreover,
improvements can also be made by accounting for protein ﬂexibility and by the use
of methods such as molecular dynamics and quantum chemistry calculations that
provide more accurate descriptions of the protein-ligand interactions60,61. At the
moment, Vina’s empirical scoring function relies on energetic factors to assign
fitness.

The use of automated computational tools will be essential for the

evaluation of complex pathways and for keeping pace with genomic data.
A critical, complementary step in computationally-based pathway determination
is experimental validation. Traditional methods employing genetic manipulation to
verify activity are slow and not practical when analyzing more than one or a few
enzymatic steps. Therefore, we employed a method of expressing and testing
each of the predicted enzymes in a crude cell extract as a means to increase
throughput. Traditional methods for enzyme characterization employ heterologous
expression followed by affinity purification. Though affinity purification can lead to
more definitive information, such as in terms of understanding reaction kinetics, it
suffers due to poor success rates and low throughput62–64. Even high-throughput,
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automated systems result in success rates as low as 20%, thus making affinity
purification impractical for keeping up with expanding gene discovery 65,66. In this
work, reactions with purified enzymes were performed to evaluate the efficacy of
using crude extracts. However, of the 9 different enzyme isolations attempted,
only AMTRF1, IPDC1, IPDC2, IALDH7, and IALDH16 could be successfully
purified. (Appendix Figure 2.7). With these purified enzymes, activity trends were
similar to those observed when using crude extracts of the proteins; the absence
of IPDC1 still quenched IAA production and IALDH16 was still significantly more
active than the other purified aldehyde dehydrogenase IALDH7. The timeconsuming nature of purification is in contrast to the simplicity and effectiveness of
using crude extracts. Here, the enzymes involved in IAA synthesis could be
identified, expressed in soluble form and tested without the need for expansive
troubleshooting. (Appendix Figure 2.8).
Having defined the IAA pathway components employed by Pantoea sp. YR343,
insights into the origin and function of the pathway can be gleaned. In the case of
the initial aminotransferase step, the presence of an additional Am-Trf1 was not
required for the reaction to progress. This is indicative of the well-known
promiscuity of aminotransferases and suggests that the initial step in IAA
metabolism is generally preserved among many organisms and used for other
metabolic reactions67. Further testing of an affinity-purified version of the Pantoea
sp. YR343 aminotransferase showed that the enzyme was capable of effectively
catalyzing the reaction but only with high concentrations of the enzyme (Appendix
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Figure 2.8). Additionally, we found that the IAA pathway in Pantoea sp. YR343
has a dependence on the IPDC PMI39_00059 (IPDC1). The importance of IPDC
is evidenced by the high concentrations of IAA produced by each in vitro reaction
containing IPDC1. This suggests that the predominant IAA pathway in YR343
utilizes PMI39_00059 and is a good target for further exploration of Pantoea sp.
YR343 IAA metabolism. This result is substantiated by previous work wherein a
full deletion of the PMI39_00059 gene generated an 80% drop in IAA 47.
The significant number of enzymes capable of catalyzing the dehydrogenation
of indole-3-pyruvate to IAA emphasizes the need for rapid and effective in vitro
tools. Sorting out the 16 different dehydrogenases by traditional genomic deletion
approaches would be prohibitively difficult. While the lynchpin step in Pantoea sp.
YR343’s IAA metabolism is catalyzed by IPDC, the organism maintains several
IALDh capable enzymes in its genome. Previous proteomic analyses of Pantoea
sp. YR343 found that up to eight IALDhs could be detected at one time 47. The
redundancy of expression may indicate that Pantoea sp. YR343 maintains multiple
pathways for IAA production. Interestingly, some of the most active enzymes found
in this work were not found to be expressed in previous studies of Pantoea sp.
YR34347. This may indicate that environmental conditions can control the
expression of particular IALDh enzymes and consequently IAA. Regardless of
other potential substrates for these IALDhs, these multiple reaction paths can be
defined by the use of computational predictions when combined with validation
using mixtures of crude enzyme extracts.
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Definition of Pantoea sp. YR343’s IAA pathway components uncovers its
potential evolutionary development. The ability to find active enzymes,
independent of genomic context, allows identification of those enzymes explicitly
designed to carry out a function as well as those that exhibit flexibility in regard to
substrate recognition. Underground metabolic functions describe potential side
reactions of an enzyme and can serve as the basis for the emergence of new
metabolic pathways without the need for significant evolutionary jumps68. In the
case of Pantoea sp. YR343, the prevalence of specific enzymatic components
related to IAA production and simultaneous lack of others shows the potential for
underground metabolic reactions to generate novel metabolic functions. For
Pantoea sp. YR343, the genes responsible for the three key conversion steps exist
outside a common operon. IAA metabolism may, therefore, be an opportunistic
phenotype generated through the crossover of a single gene in the form of IPDC
or the mutation of a homologous IPDC gene. Using a crude extract approach to
explore the metabolic potential of YR343, we were able to discern these
promiscuous functions and provide an evolutionary context for the development of
IAA metabolism in Pantoea sp. YR343.
This work has shown a rapid and scalable approach allowing for the
identification and verification of active metabolic pathways in an organism by
empirically generating functional annotations. The use of crude cell-extracts
accurately predicted metabolic pathways despite the functional redundancy and
lack of genomic context for the enzymes involved in IAA metabolism in the
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organism Pantoea sp. YR343. We expect that improvements to computational
tools will enhance the use of predictive analysis and the throughput of enzymatic
discovery. As the breadth of genomic data continues to expand so too will the need
to study such data without genetically tractable or even culturable organisms. The
work presented demonstrates the effectiveness of crude extracts as a discovery
and validation tool for both well-defined and underground metabolisms. Further,
the development of high-throughput DNA synthesis and cell-free expression from
eukaryotic cells could allow similar rapid explorations of metabolic pathways found
in eukaryotic genomes and metagenomes. In-vitro enabled analysis such as that
presented in this work, can help facilitate such studies by providing an accurate
and rapid method of testing large search spaces in short amounts of time.

Methods
Pathway and gene identification
Following a literature search, a general model of IAA production from Ltryptophan was created from a set of query proteins in order to perform a BLASTP
search against the Pantoea sp. YR343 translated genome (Appendix Table 2.1,
Figure 2.2)69. At least one BLAST hit from the literature-derived query proteins
was used to designate a protein as being related to IAA biosynthesis in Pantoea
sp. YR343. Multiple queries were used when possible. As the goal of the BLAST
analysis was to create a subset of proteins from the genome of interest for further
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analyses, a single verified enzyme was deemed sufficient for the initial annotation.
The BLAST analysis was performed by compiling a database of query proteins to
BLAST against the Pantoea sp. YR343 genome. Pantoea sp. YR343’s genome
was downloaded from GenBank. The output was parsed by searching for
potentially complete pathways in the genome using the general model created
from the query sequences. The final set of pathways was obtained after setting the
E-value cutoff at 1 × 10−25 in order to eliminate known non-IAA producers, in this
case, Escherichia coli.
Ligand-docking simulations
Protein homology models were created using the Protein Homology/analogy
Recognition Engine V 2.0 (Phyre2) by providing the target sequence from Pantoea
sp. YR343 (Appendix Table 2.2).70 The top-rated models were used, except in
cases of low template identity in 3DLigandSite to predict the substrate-binding sites
if this information was not immediately available from the template protein
structures.53 AutoDock Vina version 1.1.2 was employed to predict the interactions
of each protein and its potential binding partners.71 The search volume was set to
30×30×30 Å3 centered around the binding site predicted by 3DLigandSite; the
exhaustiveness was set to 8, and maximum energy difference was set to 3 kcal
mol−1 for each protein−ligand combination (Figure 2.2A). Successful binding
partners were determined based on both the docking poses and docking score
rankings (i.e., binding to the ligand- docking site predicted by 3DLigandSite); a set
of binding and nonbinding representative examples can be seen in (Appendix
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Figure 2.6). The lowest-energy pose was used to determine binding to the
predicted site. Proteins predicted to bind their putative substrates were
subsequently used for biochemical experiments and culled if no docked poses
were identified by Vina.
Enriched extract preparation
One Shot TOP10 Chemically Competent E. coli (ThermoFisher) was used as
the cloning strain for plasmid preparation. Each potentially IAA-related enzyme
was amplified from Pantoea sp. YR343 and inserted into the NdeI/SalI site of pET30a(+) growing on kanamycin (50 μgmL−1)(Appendix Table 2.3). All primers were
designed using NEBuilder (New England Biolabs) and purchased from IDT. Crude
cell-free extracts were prepared by culturing E. coli BL21 Star (DE3) in 2×YPTG
(16 g L−1 tryptone, 10 gL−1 yeast extract, 5 g L−1 NaCl, 7 g L−1 KH2PO4,3 gL−1
K2HPO4, 18 g L−1 glucose). Cultures of 50 mL volumes were grown using 250 mL
baffled flasks at 37 °C shaking at 250 rpm. Induction was performed using 0.1 mM
IPTG at OD600 = 0.6−0.8 and harvested after growing for 4 h at 30 °C. No
antibiotics were used during growth. Each culture was harvested by centrifugation
at 5000g for 10 min and washed twice with S30 buffer (2 g L −1 magnesium acetate,
14.05 g L−1 potassium glutamate, 0.154 g L−1 dithiothreitol (DTT), and 1.81 g L −1
Tris-acetate, pH 8.2). After the final wash, the cell pellets were weighed, flashfrozen in liquid nitrogen, and stored at −80 °C. Cell extracts were made by thawing
and resuspending the pellet in 0.8 mL of S30 buffer per gram of wet cell weight
before sonicating with 530 J mL−1 of suspension at 50% amplitude while in ice
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water. After sonication, the lysed cells were centrifuged twice at 4°C for 10 min at
21,100g. The clarified lysate was flash-frozen, and stored at −80 °C. The BL21
Star (DE3) strain was used as the base expression strain. Plasmids that did not
produce soluble protein in BL21 Star (DE3) were moved to BL21(DE3)/pLysS but
were otherwise prepared in the same manner. Both pmi39_00977 and
pmi39_04201 successfully expressed in BL21(DE3)/pLysS. After preparing each
extract, 8 ng of the soluble crude extract was loaded onto an SDS-PAGE gel in
order to verify the expression of each enzyme. His-tag purified enzyme production
required varying growth conditions outlined in the Supporting Information
(Appendix Figure 2.7).
In vitro reactions
In vitro IAA synthesis reactions were prepared by combining 50 mM Ltryptophan and ∼5mgmL−1 of each enriched extract in a 30 μL volume. Control
reactions that omitted putative reaction steps had volume shortage made up using
cell extract from E. coli. The reactions were then placed in a 28 °C incubator
shaking at 250 rpm for 24 h. Following incubation, each reaction was placed on
ice and deactivated by adjusting the pH to 2.0 with HCl. IAA was extracted by the
addition of 500 μL of ethyl acetate and vigorously vortexed. Each sample was then
incubated on ice for 5 min and briefly centrifuged to separate aqueous and organic
layers. A 400 μL portion of the organic layer was removed and dried in an analytical
vial with argon gas. Vials were stored at 4 °C before analysis. Stored samples were
resuspended in 500 μL of water before injection. Reaction components and
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conditions for purified enzyme reactions are described in detail in Appendix
Figure 2.8.
Analysis of IAA production
Quantitative analysis was performed by injecting 100 μL of suspended reaction
into an Agilent 1260 HPLC instrument equipped with an Agilent ZORBAX Eclipse
Plus C18 column and a diode array detector set at 265 nm. The mobile phase
comprised A, 0.08% trifluoroacetic acid in water; and B, acetonitrile. Analytes were
eluted at a flow rate of 1 mL min−1 with the initial eluent composition of 5% B held
for 3 min, followed by a step to 30% B, a 5 min linear gradient to 45% B followed
by a 5 min hold, a step to 75% B followed by a 1 min hold, and a step to 5% B
followed by a 6 min hold. A calibration curve was prepared using pure IAA.
Representative spectra are shown in the Supporting Information (Appendix
Figure 2.9). All chemicals were acquired from Sigma-Aldrich. Error bars were
calculated using the standard deviation from n ≥ 3 independent reactions.
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Figure 2.4. Potential IAA-related proteins were expressed in E. coli and tested for solubility. Arrows
mark the presence of the resultant gel band.

Figure 2.5. Gene neighborhoods for each of the YR343 enzymes expressed and found to be part
of an IAA reaction. Enzymes within the genomic region found to produce IAA are underlined.

36

Table 2.1. Representatives for enzymes used in BLAST analysis. Each enzyme’s name and source
are shown, as well as the number of hits found in Pantoea sp. YR343’s genome at a cutoff of 1e25.
Enzyme

Query Source

aminotransferase

>gi|329738252|gb|AEB97257.1| HisC1 [Azospirillum
brasilense]72
>gi|508716|gb|AAC36886.1| indole-3-pyruvate
decarboxylase [Azospirillum brasilense Sp245]73
>gi|837358496|gb|AKM88529.1| indolepyruvate
decarboxylase [Enterobacter cloacae]74
>tr|A0A060DWZ5|A0A060DWZ5_AZOBR Aldehyde
dehydrogenase OS=Azospirillum brasilense
GN=ABAZ39_26155 PE=3 SV=175
>gi|757149327|ref|WP_042703524.1| aldehyde
dehydrogenase [Azospirillum sp. B506]
>gi|1658175|gb|AAC49575.1| indole-3-acetaldehyde
dehydrogenase [Ustilago maydis]51
>gi|75213680|sp|Q9SZY8.1|YUC1_ARATH RecName:
Full=Probable indole-3-pyruvate monooxygenase
YUCCA1; AltName: Full=Flavin-containing
monooxygenase YUCCA1
>gi|910738333|dbj|BAS07733.1| probable indole-3pyruvate monooxygenase YUCCA3 [Arthrobacter sp.
Hiyo4]
>AGL87350.1 tryptophan 2-monooxygenase IaaM
[Pseudomonas protegens CHA0]76
>gi|4836569|gb|AAD30489.1|AF126446_4 tryptophan
monooxygenase (plasmid) [Agrobacterium fabrum str.
C58]
>gi|151292|gb|AAA25853.1| indoleacetamide hydrolase
[Pseudomonas syringae]76
>gi|12644083|sp|O81346.2|C79B2_ARATH RecName:
Full=Tryptophan N-monooxygenase 1; AltName:
Full=Cytochrome P450 79B2; AltName: Full=Tryptophan
N-hydroxylase 177
>gi|75319827|sp|Q501D8.1|C79B3_ARATH RecName:
Full=Tryptophan N-monooxygenase 2; AltName:
Full=Cytochrome P450 79B3; AltName: Full=Tryptophan
N-hydroxylase 277
>gi|426268469|gb|AFY20546.1| nitrile hydratase alpha
subunit [Pseudomonas sp. UW4]73
>gi|426268470|gb|AFY20547.1| nitrile hydratase beta
subunit [Pseudomonas sp. UW4]73
>gi|6855269|dbj|BAA90461.1| phenylacetaldoxime
dehydratase [Bacillus sp. OxB-1]78
>gi|46917226|dbj|BAD17969.1| aldoxime dehydratase
[Rhodococcus erythropolis]79
>EDU35915.1 pyridoxal-dependent decarboxylase domain
protein [Clostridium sporogenes ATCC 15579]
>4OBV_A Chain A, Ruminococcus Gnavus Tryptophan
Decarboxylase Rumgna_01526 (alpha-fmt)80
>Azospirillum brasilense Az39: ABAZ39_10795 Amine
Oxidase
>Azospirillum brasilense Sp245: AZOBR_50011 Amine
oxidase

indole-3-pyruvate
decarboxylase

indole-3acetaldehyde
dehydrogenase

indole-3-pyruvate
monooxygenase

Trp-monoxygenase

Indole acetamide
hydrolase
oxidoreductase

nitrile hydratase

acetaldoxime
dehydratase

Trp-decarboxylase

amine oxidase

YR343
Representatives
1

2

16

0

0

6

0

0

0

1

0
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Table 2.2. List of template structures used for protein homology modeling. Target sequence locus
tag designates the sequence address provided by the Joint Genome Institute’s Integrated Microbial
Genome and Microbiomes (JGI IMG/M) system. Templates used by Phyre2 are available in the
Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB). Molecular
models for ligands were downloaded from the ZINC database.
Target
Sequence/Locus

Template
Structure

PMI39_01811

1FG7

Template
Sequence
Identity
74

PMI39_00059

1OVM

57

PMI39_03777

1YI1

40

PMI39_00313

2VE5

74

PMI39_00317

2VE5

79

PMI39_00354

2W8Q

51

PMI39_00431

4O5H

37

PMI39_00617

2W8Q

52

PMI39_00725

4GO4

42

PMI39_00794

5U0M

62

PMI39_00977

5U0M

60

PMI39_01356

4O5H

41

PMI39_02889

2VE5

76

PMI39_03367

4ZZ7

57

PMI39_03939

4F9I

34

PMI39_04111

4F9I

28

PMI39_04199

3EK1

62

PMI39_04201

1BXS

37

PMI39_04236

3VZ0

49

Target Protein

Ligand

aminotransferase
indole-3-pyruvate
decarboxylase
indole-3-pyruvate
decarboxylase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase
indole-3-acetaldehyde
dehydrogenase

L-tryptophan
indole-3-pyruvate
indole-3-pyruvate
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
indole-3acetaldehyde
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Table 2.3. Enzymes identified through a BLAST search of Pantoea sp. YR343’s genome. A cutoff
of 1e-25 was used for BLAST analysis. Locus designates the relative position of each enzyme in
the YR343 genome. Enzyme title indicates the designation as an aminotransferase (Am-Trf) indole3-pyruvate decarboxylase (IPDC), or indole-3-acetaldehyde dehydrogenase (IALDh). Ligand
docking indicates the expected ability of the ligand to bind to the protein, (+) if successfully docked,
(-) if unsuccessfully docked. IAA production designates a protein as being part of an active IAA
pathway.
Enzyme Title

Locus

Amino Acid
Length

E-Value

Am-Trf1
IPDC1
IPDC2
IALDH1
IALDH2
IALDH3
IALDH4
IALDH5
IALDH6
IALDH7
IALDH8
IALDH9
IALDH10
IALDH11
IALDH12
IALDH13
IALDH14
IALDH15
IALDH16

PMI39_01811
PMI39_00059
PMI39_03777
PMI39_00313
PMI39_00317
PMI39_00354
PMI39_00431
PMI39_00617
PMI39_00725
PMI39_00794
PMI39_00977
PMI39_01356
PMI39_02889
PMI39_03367
PMI39_03939
PMI39_04111
PMI39_04199
PMI39_04201
PMI39_04236

358
550
574
146
326
489
472
480
506
488
492
506
490
501
478
458
485
489
457

1.0E-32
2.0E-38
6.0E-26
2E-26
3E-74
5E-91
2E-77
6E-87
4E-100
2E-42
1E-46
3.0E-104
1.0E-111
1E-67
6E-91
6E-56
2E-88
1E-93
3E-53

Ligand
Docking
+
+
+
+
+
+
+
+
+
+
+
-

IAA Production
+
+
+
+
+
+
+
+
+
+
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Figure 2.6. Representative examples of binary designation used to describe binding and nonbinding ligands. Designation based on lowest energy pose found by AutoDock Vina. Binding
pockets are outlined in a red circle and ligands are outlined in a black circle for highlighting
purposes. (A) 3DLigandSite prediction of ligand binding pocket for PMI39_01356. (B) Lowest
energy conformation for binding indole-3-pyruvate (purple) to PMI_01356 found by AutoDock Vina.
(C) Overlap of lowest energy binding pose for binding indole-3-pyruvate (purple) and 3DligandSite
for PMI39_01356. It should be noted that the ligand is not visible as a result of the overlap with
molecules in the binding site. D. 3DLigandSite prediction of ligand binding pocket for PMI39_04236.
E. Lowest energy conformation of non-binding indole-3-pyruvate (purple) to PMI39_04236 found
by AutoDock Vina. F. No overlap is seen between the lowest energy binding pose of indole-3pyruvate (purple) and 3DligandSite for PMI39_04236.
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Figure 2.7. SDS-PAGE gel of His-Tagged IAA-related proteins expressed in E. coli and
purified. Arrows mark the presence of the resultant gel band.
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Figure 2.8. Assembly of purified IAA producing enzymes. Purified enzymes were also
combined with crude extracts including a single aminotransferase, a single IPDC, and a single
IALDh in a crude or 6x-His purified form. Purified versions of each protein are indicated by the
addition of an H to enzyme name. “Star” surrounded by a white box corresponds to a BL21 Star
DE3 extract containing no heterologously expressed protein. “Star” extracts, were loaded to a final
concentration of 5.94 mg/mL; AMTRF1 was loaded to a final concentration of 3.8 mg/mL; IPDC1
extracts were loaded to a final concentration of 1.054 mg/mL; IPDC2 was loaded to a final
concentration 1.054 mg/mL; IALDH7 and IALDH16 were loaded to a final concentration of 4.92
mg/mL; AMTRF1-H, IPDC1-H, IPDC2-H, IALDH7-H, IALDH16-H, were all loaded to a final
concentration of 0.9 mg/mL. All reactions had final L-tryptophan concentrations of 50 mM and were
incubated at 28° C for 24 hours. Each reaction was carried out in 50 μL volumes except those
comprised of entirely purified enzymes which were 166 μL.

Figure 2.9. HPLC analysis of IAA. A. Injection of 5 μg/mL purified IAA. B. Representative cell-free
reaction following injection into HPLC.
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Chapter 3
ELUCIDATING THE POTENTIAL OF CRUDE CELL EXTRACTS
FOR PRODUCING PYRUVATE FROM GLUCOSE
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Abstract
Living systems possess a rich biochemistry that can be harnessed through
metabolic engineering to produce valuable therapeutics, fuels and fine chemicals.
Despite the tools created for this purpose, many organisms tend to be recalcitrant
to modification or difficult to optimize. Crude cellular extracts, made by lysis of
cells, possess much of the same biochemical capability, but in an easier to
manipulate context. Metabolic engineering in crude extracts, or cell-free metabolic
engineering, can harness these capabilities to feed heterologous pathways for
metabolite production and serve as a platform for pathway optimization. However,
the inherent biochemical potential of a crude extract remains ill-defined, and
consequently, the use of such extracts can result in inefficient processes and
unintended side products. Here, we show that changes in cell growth conditions
lead to changes in the enzymatic activity of crude cell extracts and result in different
abilities to produce the central biochemical precursor pyruvate when fed glucose.
Proteomic analyses coupled with metabolite measurements uncover the diverse
biochemical capabilities of these different crude extract preparations and provide
a framework for how analytical measurements can be used to inform and improve
crude extract performance. Such informed developments can allow enrichment of
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crude extracts with pathways that promote or deplete particular metabolic
processes and aid in the metabolic engineering of defined products.

Introduction
Synthetic biology aims to manipulate and exploit the existing biochemical
functions of livings organisms for desired purposes. Unfortunately, efforts to
engineer these systems to unlock their diverse metabolic potential require
developing clever methodologies to overcome aspects of the machinery that the
organism uses for survival. in vitro synthetic biology offers an alternative way to
harness an organism’s rich metabolism; it is driven by the prospect of easy to
manipulate, static systems. Livings cells require membranes, energy and building
blocks for growth, and dynamic regulation of their biochemical processes. By
removing the requirement to sustain life, in vitro systems can sidestep many of the
barriers to manipulation and present an ideal system for metabolic engineering.
In their most basic form, in vitro systems for metabolic engineering lack the
genetic material and membranes inherent to a living system. Such in vitro, or cellfree metabolic engineering (CFME), approaches enable the use of techniques
usually reserved for chemical engineering approaches such as continuous
reaction monitoring, allowing for greater control over enzymes and metabolite
concentrations81,82. Coupled with systems biology tools for flux balance analysis
and elementary mode analysis, in vitro systems present a potent platform for
bioproduction83. The absence of a cell wall and membrane facilitates the exchange
of substrate to, and product from, the system and simplifies reaction workup.
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Removal of the genome shuts down much of the cell's instructional programming
and eliminates the need to cope with a continually growing and changing system.
This enables biosynthesis pathways to be engineered in vitro, minimizing carbon
and energy lost to growth. Additionally, this minimizes the management of
feedback regulation and allows for the production of metabolites that would be
toxic to intact cells84.
Ideally, a cell-free metabolic engineering system would contain only the
components necessary to carry out the desired biochemical process. One
promising approach for complex chemical conversion uses a defined set of purified
enzymes. This methodology has been successfully demonstrated for hydrogen
production and protein synthesis among others 12,85. While recent efforts in copurification of full reaction cascades have reduced costs, any process utilizing bulk
purified proteins remains expensive86,87. To date, the use of purified components
for CFME has resulted in long-running systems capable of catalyzing reactions for
several days, but with the drawback of slow catalysis rates. Novel work by Korman
et al. on the production of limonene showcases the strengths and limitations of this
approach24. Additionally, the optimization of purified systems depends on ample
information about the pathway and the involved proteins. These methods may fail
to include accessory proteins which can improve pathway yield.
Crude cell extracts are finding increasing applications as alternatives to purified
enzyme systems for metabolic engineering. Cell growth followed by lysis and
minimal fractionation can rapidly create robust biochemical systems for a fraction
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of the cost of purified enzymes. These systems contain the same enzymes and
much of the same biochemistry as living systems and can serve as a proxy for the
engineering of metabolite production by conventional, in vivo metabolic
engineering. Recent work has demonstrated crude extracts as a platform for
bioproduction as well, due to reduced costs of scale up and their compatibility with
traditional chemical reactors6,20. Further, early work in the optimization of bacterial
cell-free protein synthesis (CFPS) systems demonstrated the ability of crude cell
extracts to energize translation in vitro through the consumption of glucose or other
glycolytic intermediates88,89. Glucose conversion is accomplished through the 10step enzymatic process of glycolysis starting with the phosphorylation of glucose
to glucose-6-phosphate and producing ATP through a series of substrate-level
phosphorylations. As shown in the aforementioned works, crude E. coli extracts
can metabolize low-cost feedstocks like glucose to provide key intermediates and
energy that can be drawn upon for myriad applications. The limits of the flexibility
of crude extracts, granted by their inherently diverse biochemistry, remain
uncertain. The proteome that enables these capabilities is only beginning to be
explored and the extract preparation variables that influence this proteome require
illumination8. Proteomic analyses coupled with metabolite measurements can be
used to identify and characterized the biochemical pathways capable of being
supported by crude extracts.
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Results and Discussion
Given that the metabolic capabilities of a cell-free extract result from the active
proteome, we hypothesized that changes to growth conditions prior to the
preparation of cell extracts would create shifts in the protein content and the
resulting metabolic abilities of the crude extracts. To investigate the protein
elements of crude cell extracts that influence precursor supply, pyruvate
biosynthesis in crude extracts was assessed. Pyruvate is both an important
compound central to carbon metabolism, linking glycolysis and Krebs cycle and a
launching point for numerous biotechnological targets 90. Proteome profiles were
obtained for the resulting crude extracts and validated by measuring the extracts’
ability to produce pyruvate after the addition of glucose.
The effects of four growth conditions on the protein content and metabolic ability
of E. coli crude extracts to produce pyruvate from glucose were assessed. Three
different growth media were used: standard rich broth (lysogeny broth, LB), M9
minimal medium with fructose (deprived fructose, DF), and extra-rich broth
(2xYTPG, YT) with cells collected at mid-log phase. Cell growth in the 2xYPTG
medium saturates at an OD600 of 8-10. Cells grown in this media were collected at
both early, (OD600 2.8) and mid-log phase (OD600 4.0), and are referred to as YT-E
and YT-M, respectively. The 2xYPTG condition, collected in early-log phase
growth, is commonly used for CFPS91. Cells collected early in log phase growth
have the greatest specific growth rate, a parameter that is suggested to influence
CFPS capabilities and may affect the abundance of glycolytic enzymes 88,89. These
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growth conditions were chosen based on variables with the potential to enrich for
glycolytic enzymes and for their frequent use for bacterial growth and related
experiments that employ crude cell extracts. The DF condition employed M9
medium with fructose as the carbon source and a starvation regimen, which is
reported to increase expression of glycolytic enzymes 94.
Effects of Growth Conditions on Proteomes of Extracts
Three biological replicates of the chosen cell extracts were digested with trypsin,
and tryptic peptides were analyzed using multidimensional protein identification
technology (MudPIT) as previously described 95. Proteins were identified and
assigned functions by matching peptides against an E. coli BL21 (DE3) genome
that had previously been annotated by KEGG's BlastKOALA software 96. After
removal of low abundance proteins and data filtering, 1170 unique proteins were
identified across all four conditions, with a core set of 796 proteins present in all
four conditions. Despite overlap in media components between several of the
growth conditions, there were measurable differences in the proteomes of the four
resulting cell-extracts. Excluding YT-M, each growth condition contained at least
10 unique proteins (Figure 3.10). As the same 2xYTPG media is used for both the
YT-M and YT-E conditions the conditions overlap strongly, a larger number of
proteins (40) are shared and are distinct from the LB and DF conditions. Further,
the rich media conditions (LB, YT-E, YT-M) share a large number of proteins (132)
that are distinct from the minimal media-based DF condition.
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In addition to energy, glycolysis provides the metabolic feedstocks for many
important pathways, including the pentose phosphate pathway and the Krebs
cycle, which in turn are the source of the carbon backbone for most primary and
secondary metabolites in bacteria. The many carbon sinks leading out of glycolysis
represent a significant draw away from pyruvate productionn. To account for the
effect of these pathways, abundances of every enzyme in the BL21 (DE3) genome
known to interact with an intermediate or product of glycolysis were analyzed for
differences. These results are compiled in supplemental Table 3.4. Figure 3.11
depicts the key differentially abundant enzymes in the cell extract proteomes that
can act on glycolytic molecules. In particular, the pathway to the aromatic amino
acid precursor shikimate was differentially represented via the pentose phosphate
pathway enzyme transaldolase (2.2.1.2) and 3-deoxy-D-arabino-2-heptulosonic
acid 7-phosphate (DAHP) synthetase (2.5.1.54).
The 10-enzyme glycolytic pathway from glucose to pyruvate begins with a
phosphorylation that can be performed by hexokinase (2.7.1.2). This enzyme is
present

in

all

four

extract

conditions,

but

the

phosphoenolpyruvate

phosphotransferase system (PTS) provides an alternative entry point into
glycolysis. PTS is a multi-protein phosphorylation cascade that in vivo results in a
phosphorylated sugar moiety using PEP as an energy source. Previous work in
vitro has demonstrated activity of the glucokinase and PEP phosphatase enzymes
in crude extracts97. PTS specificity is dictated by the non-membrane bound IIA
enzyme and membrane-bound IIBC enzyme, which often will only phosphorylate
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a single sugar, allowing for selective import of dedicated sugars. The EI PTS
protein is upregulated in both the YT-E and DF extract (Figure 3.11). While the DF
extract condition contains the fructose/mannitol-specific IIBC protein, the YT-E
extract proteome uniquely contains the glucose-specific BCII enzyme.
Analysis of individual enzymes helps to predict the flow of carbon through a cell
extract. However, analysis of individual abundances may fail to detect systematic
differences between cell extracts. Sets of phenotypically related genes can be coregulated, but individually fail pairwise tests of significance. GSEA was performed
using GO terms and Uniprot pathway designations annotated with the genome to
account for these differences98. GSEA was performed as pairs of comparisons but
some enrichments were shared amongst different comparisons and were
consolidated (Table 3.4).
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Figure 3.10. Venn diagram of differences in protein content from extracts produced from 4 different
Growth conditions. Differences in protein content reported after filtering out low abundance
proteins. There is a core set of 796 proteins present in all four conditions. The different conditions
contain a small number of unique proteins, with the exception of YT-M, which may be a subset of
the YT-E conditions. The cell extracts grown in rich media (YT-E, YT-M, LB) share a greater number
of proteins (132) than any other subset of these conditions.
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Figure 3.11. Proteomic assessment of the potential in vitro metabolic fates of glycolytic
intermediates. A. Enzymatic steps are represented by Enzyme Commission (EC) numbers. Each
EC number and reaction arrow corresponds to at least one protein detected in all growth conditions.
Upregulated steps are represented by red, green, orange, and blue colored arrows for YT-E, YTM, DF, and LB growth conditions, respectively. Only differentially abundant sinks of glycolytic
intermediates are shown. Cofactors are depicted as colored circles, full yellow circle, ATP; half
yellow circle, ADP; full blue circle, NADH; half blue circle, NAD+; “Pi” within the empty circle,
inorganic phosphate. B.) Phosphoenolpyruvate transferase system reaction schematic. General
PEP phosphotransferase enzyme, EI, is upregulated in both the YT-E and DF cell extracts. HPr
phosphotransferase protein and glucose-specific IIA protein are only present in the YT-E condition.
Enrichment is represented by NSAFs.
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Table 3.4. Summary of gene set enrichment analysis. Results are based on biological process and
molecular function GO terms and Uniprot Superpathway annotations. Table represents all
enrichments found with a false discovery rate < 25% in pairwise comparisons. Enrichments found
in more than one comparison have been combined.
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Pyruvate Production
We first investigated the glycolytic activity of the differentially prepared crude
extracts by introducing them to a standard reaction mixture of the necessary cofactors NAD+ and ATP as well as a set of buffering reagents and salts in order to
confirm their ability to consume glucose and drive glycolysis towards pyruvate
production. Over the course of a 24-hour incubation, aliquots of each reaction were
halted using TCA, and quantified for glucose by HPLC analyses. Each extract
broke down different amounts of glucose with YT-E consuming the largest amount
at 147 mM at an average rate of 6.75 mM h¯ 1 over a 24 hour period (Figure 3.12).
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Figure 3.12. Simultaneous measurements of glucose and pyruvate at various time points over a
24-hour period. Extracts are shown here as orange, blue, green and red colored symbols and lines
for DF, LB, YT-M, and YT-E growth conditions, respectively. Data and standard deviation for the
time course reactions were acquired using n=3 biological replicates. Solid lines indicate glucose
time courses and dashed lines indicate those for pyruvate.

The concentration of pyruvate was simultaneously analyzed along with glucose
consumption for each of the prepared extracts over a 24-hour time period. As
would be expected, the final concentrations of pyruvate complemented the
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consumption rate of glucose with the YT-E extract producing the greatest amount
of pyruvate at 21.29 mM. The DF extract produced the least amount of pyruvate
at 0.73 mM and the values for LB and YT-M fell in between. However, the
conversion of glucose to pyruvate was not quantitative. The differences in the
extract’s ability to both consume glucose and produce pyruvate, implies that CFME
extracts can have a variety of metabolic capabilities based on their different protein
content that results from changes in the cell growth conditions.

Table 3.5. Percent glucose consumed and the percent glucose converted to pooled pyruvate.
Conversion amounts were determined using n=3 biological replicates. Data acquired after 24 hours
of feeding the reactions 250 mM glucose and measuring the remaining glucose concentration and
the amount of pyruvate produced, respectively. The percent of glucose converted to pyruvate and
downstream metabolism was determined after measuring the consumption rate of 25 mM pyruvate
after 24 hours in the absence of glucose. aGlucose conversion was calculated by measuring pooled
pyruvate after 24 h and converting to glucose. bThe expected glucose used to make the pyruvate
consumed by downstream metabolism was combined with the glucose consumed in order to
produce the pooled pyruvate to account for the breakdown of pyruvate due to downstream
metabolism and show the extract’s ability to synthesize glucose from pyruvate without the sink of
downstream metabolism.

Extract

DF
LB
YT-M
YT-E

Percentage of Glu
Consumed

15.55%
25.74%
18.52%
61.00%

Percentage of
Consumed Glucose
Converted to
Pooled Pyruvatea

0.92%
3.50%
4.58%
6.57%

Percentage of
Consumed
Glucose Converted
to Pyruvate and
Downstream
Metabolismb

24.55%
12.60%
28.83%
13.45%

Due to the breadth of potential metabolic pathways present in the crude extract,
we next sought to understand if the presence of the targeted metabolite, pyruvate,
was maintained at a sufficient level to be an adequate feedstock for subsequent
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metabolic conversion. To test the activity of the extract’s downstream pyruvate
consumption pathways, we exogenously added pyruvate and co-factors to each
extract and measured total pyruvate consumption after a 24-hour period (Figure
3.13). As suggested from the proteomic analyses, sink pathways for glycolytic
intermediates are well represented in the crude extracts. Calculation of the glucose
to pooled pyruvate conversion rates and the pyruvate consumption rates indicate
significant differences in the fraction of glucose that passes through pyruvate
(Table 3.5). Each of the extracts was capable of consuming a large portion of the
pyruvate provided regardless of the extract preparation condition. The YT-M
extract was capable of consuming pyruvate at nearly the same rate as the YT-E
extract, 0.96 mM h-1, and 0.93 mM h-1 respectively, despite the YT-E extract
producing a larger pool of pyruvate after 24-hours.

Figure 3.13. Simultaneously measurements of glucose and pyruvate at various time points over a
24-hour period. Extracts are shown here as orange, blue, green, and red colored symbols and lines
for DF, LB, YT-M and YT-E growth conditions, respectively. Data and standard deviation for the
time course reactions were acquired using n=3 biological replicates. Solid lines indicate glucose
time courses and dashed lines indicate those for pyruvate.
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The DF condition was capable of breaking down pyruvate nearly 26 times faster
than it could be produced indicating that the extract is relatively enriched for
pathways downstream of pyruvate, in addition to those that deplete glycolytic
intermediates. In the YT-M and the YT-E conditions, the consumption of pyruvate
was greater than the DF condition, however, the potential consumption from
downstream pathways was not enough to deplete the pyruvate reservoirs created
by the extract. The YT-E extract, in particular, was able to maintain a reservoir of
pyruvate that nearly matched the total pyruvate that it could consume within a 24hour time frame.
The metabolic potential of crude extract preparations and their use for
metabolite production can be assessed through an exploration of their proteomic
and metabolic profiles. Despite progress in the use of crude extracts for protein
expression, the actual content of a crude extract and its metabolic potential is
poorly understood. We sought to address this deficiency by exploring the protein
profiles of different cell extract preparations and assess their ability to produce
pyruvate from glucose in CFME. As a central player in a variety of cellular
processes, pyruvate is not only a key indicator of a crude extract’s glycolytic
potential, but also an important proxy for the extract’s ability to produce small
molecules of commercial interest90. To explore the optimization of precursor
production in cell-free extracts, we modulated cell growth conditions in order to
create global changes in an extract’s protein content. Given the static nature of the
protein content in crude extracts, understanding the proteomic and metabolic
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potential of these systems can provide an effective platform onto which
heterologous pathways could be engineered with predictable effects and high
yields.
The ability of each crude extract to potentially break down glucose is evident
from proteomic analyses.

All growth conditions resulted in extracts with the

presence of at least a minimal set of the ten enzymes required for converting
glucose to pyruvate.

Confirmation of glycolytic activity was supported by

metabolite analyses. The different extracts all converted glucose to pyruvate in
the presence of the appropriate cofactors. Further, a nearly thirty-fold difference
in the amount of pooled pyruvate, after 24-hours, is observed when comparing the
different crude extracts; ranging from 21.29 mM in YT-E and 0.73 mM in DF. These
comparisons showcase the importance of growth conditions when preparing an
extract. Proteomic analyses aid in interpreting the effect of these changes. For
example, the differences in methodology to create the YT-E and the YT-M extracts
are seemingly minor, with the YT-E extract being harvested at an earlier point in
the growth phase when compared to YT-M. However, the effects of this change
significantly impact the metabolic pathways present in the extract. While both the
YT-M and the YT-E extracts can break down pyruvate at a similar rate, the
production of pooled pyruvate in the YT-M extract is only 1/5th that of the YT-E
extracts. This difference can be attributed to the prevalence of the glucose-specific
PTS system, which may serve as both an entry and exit for glycolysis and account
for both the increased glucose consumption and the increased production of
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pyruvate in the YT-E extract. The absence of the HPr protein in the DF condition
removes this alternative glucose consumption pathway despite a relative
abundance of the glucose-specific proteins.
Glucose consumption in cell-free systems can be a robust process and has
been shown in previous studies88. As confirmed here, 15-60% of added glucose
can be metabolized by crude extract preparations. Biosynthesis and degradation
pathways drawing from central metabolism, such as those for nucleotides, lipids
and amino acids, can affect the flow of carbon to pyruvate in the DF cell extract.
Proteome analyses indicated that the DF cell extract, which was grown on a
minimal medium, is enriched in amino acid and nucleotide biosynthesis pathways
that are not prevalent in the other extract preparations (Figure 3.11,
Supplemental Table S3). These pathways rely upon intermediates from glycolysis
for their carbon backbones and decrease overall flux towards pyruvate. The
upregulation of the glycolytic enzymes combined with the presence of shunting
pathways show a clear path by which the DF extract could produce pyruvate, but
not accumulate pyruvate, in the same fashion as the YT-E extract where the
overwhelming amount of the produced pyruvate was shunted downstream.
Each tested growth condition resulted in an extract capable of breaking down
pyruvate, which depletes the pool of this metabolite. The different crude extracts
were capable of consuming up to 90% of added pyruvate. After accounting for this
consumption, the overall production rates of pyruvate for the DF, LB, YT-M, and
YT-E extracts are 0.82 mM h¯1, 0.71 mM h¯1, 1.14 mM h¯1, and 1.82 mM h¯1,
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respectively. None of the consumed pyruvate appears to be converted back to
glucose. As previously noted, the production of pyruvate from PEP is effectively
irreversible99. The pyruvate is likely funneled into downstream metabolic pathways,
and analyses of proteomic information provided insights. GSEA reveals that
carbohydrate metabolism, specifically the Krebs cycle was up-regulated in the LB
extract. Conversely, the YT-E and YT-M extracts were relatively depleted in the
Krebs cycle as is common for cells in exponential growth 100. Interestingly, a
component of the pyruvate dehydrogenase complex (2.3.1.12) was upregulated in
both the YT-E and YT-M extracts, potentially indicating the channeling of pyruvate
to acetyl-CoA. Rapid growth, which might be expected under conditions with
abundant resources, results in a need for biomass components, the biosynthesis
of which both starts from intermediates in glycolysis, and heavily deplete the
central precursors therein101. Extracts derived from rapidly reproducing cells can
result in active biomass accumulation pathways and can result in a significant drain
on both feed metabolites and cofactors in metabolic engineering endeavors. These
pathways likely lead to the increased consumption of pyruvate observed in the YTE and YT-M extracts. While sink pathways draw carbon away from central
metabolism, their effect may be mitigated by the prevalence of upstream pathways
providing a balancing effect. The LB extract is upregulated in both anaplerotic
pathways and gluconeogenesis (4.1.3.1, 4.1.1.49, 3.1.3.11) and consumed
comparatively less pyruvate than the other extracts.
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The use of proteomic and biochemical analyses to describe the metabolic
capabilities of a crude extract provides a useful framework for realizing an extract’s
potential applications and optimization. Changes, either genetic or to growth
conditions, can be made to further tailor a crude extract for the desired function.
Here, it is evident that growth on a minimal medium results in the expression of
many sink pathways for glycolytic intermediates. Moreover, it appears specific
growth rate, which has been previously examined as a key variable in CFPS
extract preparation, plays a role in reducing sinks due to the Krebs cycle, but at
the price of directing flux towards undetermined biomass accumulation
pathways92. Proteomic analysis is a robust technique for determining candidates
for genetic manipulation and can guide in vivo protein overexpression or
knockdowns in source strains that will affect the flux of small molecules after
extract preparation. Alternative strategies, such as targeted protein degradation
and pull downs, have been described for the removal of deleterious proteins from
crude extracts after cell lysis to avoid negatively impacting cell growth and
survival102. Crude extracts made from high-yielding in vivo pyruvate production
strains represent another opportunity to use in vitro synthetic biology to enable
metabolic engineering103,104. Some of the highest producing strains are limited in
their genetic tractability, but omics data can provide strong candidates for
modification and minimize the amount of genetic engineering needed.
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Conclusion
Critically analyzing the central precursors of cell-free systems as well as how
the conditions in which these extracts are grown can impact the metabolic potential
of a cell-free system due to changes in the underlying proteomic content. Notably,
we demonstrate that simple changes in cell-free extract preparation can result in
profound differences in metabolite pooling. Further, these changes in extract
preparation have the potential to deplete important precursors that could be used
for synthesis of a final product. These different metabolic characteristics can be
interpreted through the combined use proteomics and metabolomics techniques.
These analytical measurements further our understanding of the composition of
cell-free extracts and provide a rich dataset from which to engineer improved
solutions for metabolite production. These tools can guide genetic manipulations
and strain optimization conditions for maximizing the production of pyruvate, as
well as other important biosynthetic precursors. Feasibly, effective development of
crude extracts can lead to a general platform suitable for testing biochemical
pathways and for the production of useful metabolites.

Methods
Cell-free extract preparation
Cell extracts were prepared from E. coli BL21 Star (DE3) grown at 37 °C in one
of three media: M9-fructose (11.1 mg L-1, CaCl2, 0.120 g L-1 MgSO4, 4.0 g L-1
fructose, 0.15 g L-1 KH2PO4, 3.39 g L-1 Na2HPO4, 0.25 g L-1 NaCl, 0.5 g L-1 NH4Cl);
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lysogeny broth (LB: 10 g L-1 tryptone, 5 g L-1 yeast extract, 10 g L-1 NaCl); or
2xYPTG (16 g L-1 tryptone, 10 g L-1 yeast extract, 5 g L-1 NaCl, 7 g L-1 KH2PO4, 3
gL-1 K2HPO4, 18 g L

-1

glucose). The extracts prepared from these media are

referred to as, DF, LB, and YT, respectively. Cell extracts were prepared by
harvesting 50-mL cultures grown in baffled Erlenmeyer flasks to an OD600 of 1.0
for DF, 2.0 for LB, or 4.0 for mid-log phase YT (YT-M). The DF cells were
additionally transferred to M9 salt solution containing no fructose for 24 hours
before harvesting. A second-type of YT extract, YT-E, was prepared by growing
cells to an OD600 of 2.8 and harvesting. Cells were harvested by centrifugation at
5000x g for 10 min in 50 mL volumes and washed twice with S30 buffer (14 mM
magnesium acetate, 60 mM potassium glutamate, 1 mM dithiothreitol (DTT) and
10 mM Tris-acetate, pH 8.2) by resuspension and centrifugation. After the final
centrifugation, pellets were weighed, flash-frozen in liquid nitrogen and stored at –
80 °C. For extract preparation, cells were thawed and resuspended in 0.8 mL of
S30 buffer per mg of cell wet weight before sonicating using 530 joules per mL of
suspension at 50% tip amplitude with ice water cooling. After sonication, the cellslurry was centrifuged twice for 10 minutes at 21,100 x g at 4 °C, aliquoted, flashfrozen and stored at –80 °C.
Cell-free reactions
Cell free glucose conversion reactions were carried out at 37 °C for 24 hours in
25 μL volumes with a final concentration 250 mM glucose, 18 mM magnesium
glutamate, 15 mM ammonium glutamate, 195 mM potassium glutamate, 1 mM
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ATP, 150 mM Bis-Tris, 1 mM NAD+, 10 mM dipotassium phosphate. Pyruvate
consumption reactions were carried out using the same conditions and reagents,
with the exception of glucose being replaced with 25 mM pyruvate. Growth
enriched extracts were added to a final protein concentration of 4 mg mL -1. The
reactions were quenched by the addition of an equal volume of 5% trichloroacetic
acid. The supernatant after centrifugation at 11,000 x g for 15 minutes was used
for analytical measurements.
Analytical measurements
High-performance liquid chromatography (HPLC) was used to measure
pyruvate and glucose in the cell-free reactions. An Agilent 1260 series HPLC
system equipped with a diode array UV-visible detector (Agilent, Santa Clara, CA)
reading at 191 nm, with an Aminex HPX 87-H column (Bio-Rad, Hercules, CA)
was used for the quantifications. Analytes were eluted with isocratic 5 mM sulfuric
acid at a flow rate of 0.55 mL min–1 at 35 °C for 25 min.
Proteomics
CFME extracts were denatured with 6 M guanidinium chloride for 1 h at 60 °C
and allowed to cool to room temperature. Cysteines were reduced by incubation
in 2 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP) for 20 min at room
temperature and carboxamidomethylated by incubation in 10 mM iodoacetamide
in the dark for 15 min. Samples were diluted with 5 volumes of digestion buffer (50
mM Tris-HCl, 10 mM CaCl2, pH 7.6), and the proteins were digested by adding
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trypsin at a 1:50 weight ratio (based on Bradford assay) with overnight incubation
at 37 °C. An additional identical amount of trypsin was then added, with an
additional 4 h incubation at 37 °C. Trypsin was inactivated by the addition of formic
acid to a final concentration of 0.1%. Tryptic peptides were obtained by
centrifugation through a 10 kDa molecular weight cutoff filter (Microcon YM-10,
Millipore, Billerica MA) for 20 min at 14,000 ✕ g. 50 µg of tryptic digests were
loaded onto a strong cation exchange resin (SCX) (Luna, Phenomenex, Torrance,
CA)

and

desalted.

Digests

were

analyzed

by

two-dimensional

liquid

chromatography-tandem mass spectrometry (Washburn et al., 2001). Briefly,
peptides were eluted from SCX resin with an eleven-step gradient of aqueous
ammonium acetate (50 mM to 500 mM) onto reverse-phase C18 resin (Aqua,
Phenomenex, Torrance, CA). Peptides were eluted from reverse-phase over two
hours with a gradient from 100% solvent A (5% CH 3CN, 0.1% formic acid in water)
to 50:50 solvent A: solvent B (70% CH3CN, 0.1% formic acid in water). Peptides
eluted from the column were introduced into the linear ion trap mass spectrometer
(LTQ-XL, ThermoScientific) by nanoelectrospray. Peptide identifications were
obtained from MS/MS spectra using the program Myrimatch (version 2.1.138) and
compared against the Escherichia coli BL21 (DE3) proteome (UP000002032), and
protein identifications were assembled from peptide identifications using IDPicker,
version 3.1.599 (Ma et al., 2009; Tabb et al., 2007). KEGG Orthologies and
Enzyme Commission numbers were assigned by BlastKOALA (Kanehisa et al.,
2016). Full tables of detected proteins, tryptic peptides and KEGG orthology
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assignments are deposited in Supplemental Tables S1 and S2. Descriptions of
these tables and their legends are supplied in the appendix.
Statistical analysis
Three biological replicates were used for all HPLC measurements. Error bars in
figures represent ± 1σ. Proteome analyses were likewise performed on three
biological replicates. Significant changes in protein abundance for a given pair of
treatments were identified using T-tests (2-tailed, unpaired, equal variances) on
log10-transformed normalized spectral abundance factor (NSAF) value, with
Benjamini-Hochberg correction for multiple hypothesis testing. Differential
abundance was determined by ANOVA and direction of regulation by comparisons
of prevalence value as previously described 8. Gene set enrichment analysis
(GSEA) was performed using the tools designed by Subramanian et al.
(Subramanian et al., 2005). In brief, GSEA was performed using gene ontology
(GO) terms and Uniprot pathway and super pathway annotations as pairwise
comparisons of log10 transformed NSAF values between each set of extracts.
Gene sets enriched with a false discovery rate < 25% were retained.
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Appendix

68

The following contents can be found in the original publication of this work as,
Legend for Supplemental Table S1, Legend for Supplemental Table S2, Legend
for Supplemental Table S3 and relate to the supplementary data therein.

Supplemental Table S1 (prot_supp_table.xlsx) includes a complete listing of the
1,763 proteins (one per row) identified by full proteome characterizations of crude
cell extracts prepared from four different growth conditions. Columns in this table
are:
Protein: protein identifier from FASTA file used for Myrimatch searches (see
Methods: 2.4 Proteomics)
A set of 7 columns listing quantities measured or calculated from each LC-MS/MS
measurement; “NA” indicates that a protein was not identified in that LC-MS/MS
analysis:
•

•
•
•
•
•
•

SqC: Sequence Count, the number of identified tryptic peptides for the
protein, with different charge states of the same peptide counting as 1
sequence. Each identified modified form of a peptide is counted as a
separate sequence.
uSqC: number of identified sequences that are unique within the FASTA
file to this protein
SpC: Spectrum Count, the number of identified tandem mass spectra for
this protein
uSpC: Spectrum Count of peptides that are unique within the FASTA file to
this protein
dSpC: Distributed Spectrum Count, modified to account for peptides shared
with other proteins105.
PercentCoverage: fraction of protein sequence covered by detected tryptic
peptides
NSAF: Normalized Spectral Abundance Factor: corrected and normalized
estimate of protein abundance. NSAF sums to 1 across all proteins in a
single run106.
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Headers for each of these 7 columns include the sample identifier:
•

YT-E 1, YT-E 2, YT-E 3: LC-MS/MS biological replicates of standard
Escherichia coli cell-free protein synthesis crude extract. Extract was grown
on 2xYTPG media and collected during early-log phase.
• YT-M 1, YT-M 2, YT-M 3: LC-MS/MS biological replicates of E. coli crude
extract. Extract was grown on 2xYTPG media and collected during mid-log
phase.
• DF 1, DF 2, DF 3: LC-MS/MS biological replicates of E. coli crude extract.
Extract was grown on M9 minimal media with fructose and collected during
mid-log phase.
• LB 1, LB 2, LB 3: LC-MS/MS biological replicates of E. coli crude extract.
Extract was grown on M9 minimal media with fructose and collected during
mid-log phase.
Other_prots: Proteins in the FASTA file that share identified tryptic peptide
sequence(s) with this protein Length: number of amino acids in the protein
Description: protein description from identifier line of the protein FASTA file
KO: K number orthology term assigned by BLASTKOALA96
Score: weighted sum BLAST bit scores for each K number group
Supplemental Table S2 (pep_supp.xlsx) lists tryptic peptides identified in full
proteome characterizations of crude cell extracts prepared from four different
growth conditions. Columns in this table are:
Sequence: amino acid sequence of the peptide. A number in square brackets
indicates a modification in mass to the preceding amino acid.
Z: charge state of the peptide.
A set of 3 columns listing quantities measured or calculated from each LC-MS/MS
measurement; “NA” indicates that a peptide was not identified in that LC-MS/MS
analysis:
•

Q: maximum Q value (IDPicker false discovery estimate for peptidespectrum matches) among identifications of this peptide (peptide-spectrum
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•
•

matches) that pass filters documented in Methods: Proteomics data
analysis.
Precursor m/z: mass-to-charge ratio of the precursor ion that was
fragmented, averaged across the spectra identified for this peptide.
Spectra: Number of tandem mass spectra matched with this peptide
sequence by Myrimatch.

Headers for each of these 3 columns include a sample identifier, listed above for
Supplemental Table 1.
Proteins: Proteins that contain this amino acid sequence
Supplemental Table S3 (glycolytic_sink_statistics.xlsx) lists each enzyme in E.
coli proteome UP000002032, as both an EC number and proteome accession
number, that consumes or produces an intermediate of glycolysis. Columns in this
table are:
Glycolytic intermediate and Enzyme Commission number: lists the
intermediate produced or consume and the EC number of the enzyme involved.
Protein accession number: the accession number for the protein in the provided
proteome.
Average NSAF: as in Table S1. NSAFs were omitted for proteins that fell beneath
the abundance threshold or were not detected.
ANOVA: Benjamini-Hochberg corrected p-values for One-way ANOVA. Values
were omitted for corrected p-values > 0.05.
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Chapter 4
A LYSATE PROTEOME
ENGINEERING STRATEGY FOR
ENHANCING CELL-FREE
METABOLITE PRODUCTION
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A version of this chapter by David C. Garcia, Jaime Lorenzo N. Dinglasan, Him
Shrestha, Paul E. Abraham, Robert L. Hettich, and Mitchel J. Doktycz, was
submitted to Metabolic Engineering Communications and is available as:
Garcia, D. C.; Dinglasan J. N.; Shrestha. H.; Abraham, P. E.; Hettich, R. L.;
Doktycz M. J. A Lysate Proteome Engineering Strategy for Enhancing Cell-Free
Metabolite Production. bioRxiv 2020.

Abstract
Cell-free systems present a significant opportunity to harness the metabolic
potential of diverse organisms. Removing the cellular context provides the ability
to produce metabolites without the need to maintain cell viability and enables
metabolic engineers to explore novel metabolic systems. Crude extracts maintain
much of a cell’s metabolic capabilities. However, only limited tools are available
for engineering the contents of the extracts used for cell-free systems. Thus, our
ability to take full advantage of the potential of crude extracts for cell-free metabolic
engineering is limited.

Here, we employ Multiplex Automated Genomic

Engineering (MAGE) to allow selective removal of proteins from crude extracts to
specifically direct metabolite production. Specific edits to central metabolism are
possible without significantly impacting cell growth. Selective removal of pyruvate
degrading enzymes results in engineered crude extracts that are capable of 10fold increases of pyruvate production when compared to the non-engineered
extract. The described approach melds the tools of systems and synthetic biology
for the development of cell-free metabolic engineering into a significant platform
for both bio-prototyping and bioproduction.
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Introduction
Driven by the prospect of biological systems that can be easily manipulated, the
application of synthetic biology tools to in vitro environments offers a promising
approach to harnessing an organism’s rich metabolic potential 107. Cell-free
systems use cytoplasmic components, devoid of genetic material and membranes,
as a means of producing complex chemical transformations. While living cells
require membranes, growth substrates, and biochemical regulation, in vitro
systems sidestep these barriers to manipulation and present an opportunity to
explicitly define a system for creating novel proteins and metabolites 108. In this
way, cell-free metabolic engineering (CFME) can use the organism’s existing
biochemical functions and further combine these capabilities with heterologous
pathways to produce chemical precursors, biofuels, and pharmaceuticals.
Efforts to engineer cell-free systems have taken different approaches. Ideally, a
CFME system would contain a minimal set of components necessary to carry out
a desired biochemical process. Previous approaches employed a defined set of
purified enzymes for producing high-yielding chemical conversions and have
successfully demonstrated a variety of capabilities including chemical production
and protein synthesis22,109. Constructing complex, multistep pathways require
significant development and upfront costs as utilizing purified proteins at scale
remains costly24. Further, these purified component systems can exhibit slow
catalysis rates, possibly due to the lack of accessory proteins and appropriate
protein concentrations capable of improving pathway yield 24. Nevertheless, long74

running CFME systems that can catalyze multi-step reaction pathways for days
have been developed22.
The use of crude cell extracts presents an alternative approach to CFME.
Simple cell lysis and minimal fractionation can be rapidly carried out and result in
complex enzyme mixtures for a fraction of the cost of purified components 7,25,91.
Crude extract systems are generally derived from both commonly used cell-free
model organisms, such as E. coli BL21 Star (DE3), contain a similar biochemistry
to the cell of origin, and can serve as both prototyping tools for in vivo metabolic
engineering and as bioproduction platforms 8,19,110,111. Cell-free systems work well
for this purpose as extracts can be modularly assembled with those enriched for
metabolic pathways in order to produce a specific molecule. Additionally, their
compatibility with chemical reactors and ability to consume low-cost feedstocks
have popularized them as potential sources for industrial production 9,112,113.
While environmental variables of a cell-free system can easily be manipulated,
the proteomic content of the crude extract is more difficult to engineer. Genetic
manipulation of a donor strain can substantially impact its growth and function as
a bioproduction system30. It has been noted previously that simple variations in
growth conditions can lead to complex changes in the proteome and significant
differences in metabolite flux in the resulting crude extracts 30,114. Further, specific
enzymes can be added or expressed in an extract to further define metabolite
production7,107.

However, removing specific proteins is challenging as gene

deletions can affect the growth and global expression of the donor cell. In
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particular, deletions to central metabolism can be lethal, which severely limits the
ability to direct flux from simple carbon sources. The inability to remove specific
pathways from CFME reactions poses a significant constraint and limits the use of
crude extracts for bioproduction7,30. Tools that allow shaping of the proteome and
tailoring of specific pathways will be critical in enabling the use of crude extract
systems for metabolic engineering applications.
In this work, we describe the use of genome engineering, specifically MAGE, to
enable the removal of particular proteins from crude extracts for CFME. 6xHis-tags
are incorporated into proteins that are expected to consume pyruvate and are used
for the affinity-based removal of these proteins following cell lysis. Pyruvate, a key
connection point in central carbon metabolism, was chosen due to its role linking
glycolysis and the Krebs cycle, as well as its relevance as a central precursor for
numerous products90,104. The use of genome engineering results in a modified
proteome capable of producing engineered metabolic phenotypes with minimal
impact on the viability of the donor cell (Figure 4.14)115,116. This general strategy
was demonstrated using E. coli BL21 Star (DE3) as a chassis due to its prevalent
use for cell-free synthetic biology.
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Figure 4.14. Overview of approaches to preparing lysates for cell-free metabolic engineering. A.
Complex metabolism present in E. coli lysates harnessed for cell-free metabolite production can
compromise central metabolic precursor yields. B & C. Cell-free metabolic engineering approaches
seek to reduce lysate complexity in order to redirect carbon flux and pool central metabolic
precursors. B. The standard CFME approach reduces lysate complexity by deleting target genes
from the source strain, often resulting in growth impaired or lethal phenotypes due to the inability
to remove essential genes. This can require multiple design-build-test cycles. C. The new approach
involves engineering source strains to endogenously express recognition sequences, such as
6xHis-tags, into target proteins for subsequent removal from lysates through affinity purification,
resulting in minimal to no impact on source strain growth and enhanced pooling of specific
metabolic products.

Results and Discussion
Pyruvate sits at the biochemical junction of glycolysis and the TCA cycle. It is
a key intermediate in producing many food, cosmetic, pharmaceutical and
agricultural products whose improved production has been largely unexplored in
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cell-free systems90,104. In order to create a pyruvate pooling phenotype in an E. coli
cell-free extract, four proteins were chosen as targets for removal, LdhA, PpsA
AceE, and PflB, due to their direct role in consuming pyruvate (Table 4.6) (Figure
4.15)104. 6xHis tags were fused on either the amino or carboxyl terminus by genetic
modification based on an evaluation of literature related to previous purification
attempts or crystal structures to find a non-inhibitory location (Table 4.6)117,118.

Table 4.6. Gene and protein information for MAGE targets with
a potential effect on pyruvate metabolism.

6xHisTagged
Terminus

MW
(kDa)

Gene

Protein

pflB

Pyruvate formate- N-Terminal
lyase
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ldhA

D-lactate
dehydrogenase

N-Terminal

36.53

ppsA

Phosphoenolpyruv
ate synthase

N-Terminal

87.43

aceE

Pyruvate
C-Terminal
dehydrogenase E1

99.66
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Figure 4.15. Glycolysis and engineered pathway nodes. The numbers 1, 2, 3, and 4 indicate the
enzymes pflB, ldhA, ppsA, aceE.

The traditional cell-free protein synthesis chassis E. coli BL21 Star(DE3) was
chosen as the source strain for creating edited extracts. For genome engineering,
the pORTMAGE system was used instead of a genome integrated system due to
its potential transferability to multiple donor organisms including E. coli BL21
Star(DE3)

119,120

. Additionally, pORTMAGE is curable following genome

engineering and relieves the metabolic burden on the cell that can be imparted
due to plasmid maintenance121. Colony screening was performed using MASCPCR and further verified using Sanger sequencing (Figure 4.16 A and B)122. A
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total of 5 strains were used for this work. (Table 4.7). The strains included 6xHis1 (6xHis-pflB), 6xHis-2 (6xHis-pflB-ldhA), 6xHis-3 (6xHis-pflB-ldhA-ppsA), 6xHis-4
(6xHis-pflB-ldhA-ppsA-aceE) and 6xHis-ldhA. 60 rounds of MAGE were needed to
incorporate all four of the tags into the E. coli genome (Figure 4.16 A, B, and C)
(Table 4.7). This is high when compared to studies producing single nucleotide
changes, but in line with other efforts using 6xHis-tags with a genome incorporated
MAGE system109.

Figure 4.16. Source strain multiplex genome engineering and expected metabolic phenotypes of
derived lysates post-reduction. A. Strain construction course by MAGE cycling culminating with the
6xHis-4 containing all 4 tags. Each arrow designates the strain being taken through the MAGE
process with the oligos used to transform each strain above the arrow. B. MASC-PCR results for
additive mutations using primers specifically designed for the 6xHis-tagged version of the gene. C.
Expected metabolic phenotypes present in WT and engineered lysate proteomes after the
reduction of lysates derived from all generated strains.
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Table 4.7. Strains created for lysate engineering
study.

Strain
Name
6xHis-ldh
6xHis-1
6xHis-2

Background
BL21 Star(DE3)
BL21 Star(DE3)
BL21 Star(DE3)

6xHis-3

BL21 Star(DE3)

6xHis-4

BL21 Star(DE3)

Modified
Genes
his-ldhA,
his-pflB
his-ldhA,
his-pflB
his-ldhA,
his-pflB,
his-ppsa
his-ldhA,
his-pflB,
his-ppsa,
his-aceE

After curing each strain of the pORTMAGE plasmid, potential inhibitory effects
on growth caused by the expression of tagged proteins were evaluated. Though
the presence of the polyhistidine tags has previously been observed to cause
growth defects due to the stability of tagged proteins, none of the cells produced
for this work showed a significant drop in growth rate (Appendix Figure
4.19)123,124.
The effect of proteome reduction on the extract’s metabolic profile was then
tested by measurement of pyruvate accumulation in a CFME reaction mix. Early
time points show a high accumulation of pyruvate starting at 2 hours and
continuing up to 12 hours before the concentration of the metabolite decreases
(Figure 4.17). After 8 hours, the reduced 6xHis-4 extract reaches a maximum
concentration of 25 mM pyruvate from an initial glucose concentration of 100 mM
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(Figure 4.17 A and B). The accumulation of pyruvate at early time points is
consistent with a reduction in the proteins capable of consuming pyruvate. In
general, the extracts reduced for ldhA show significant increases in pyruvate
pooling potentially indicating it is the main in vitro consumer of pyruvate.
Interestingly, the effect was not permanent as the pyruvate concentration
decreased in the reduced extracts after 12 hours, falling to 6.41 mM for 6xHis-2,
7.2 mM for 6xHis-3, and complete consumption for 6xHis-4 by 24 h (Figure 4.17).
For the unreduced strains, extracts not incubated with cobalt beads, little to no
pooling of pyruvate occurred from 0 to 8 hours; a result that is corroborated by
previous observations of E. coli extracts30. This is notable as the highest pyruvate
concentration between 0 to 8 hours, 4.15 mM in unreduced 6xHis-3, was 5-fold
lower than reduced versions of 6xHis-2, 6xHis-3, and 6xHis-4 (Figure 4.17).
The rapid accumulation of pyruvate in the reduced strains after 4 hours leads to
a relatively stable concentration in reduced 6xHis-2, 6xHis-3, and 6xHis-4 extracts
showing that the reduced lysates are able to maintain an equilibrium between
glucose and pyruvate concentrations (Figure 4.17, Appendix Figure 4.20). The
rapid consumption of pyruvate following 12 hours for the 6xHis-2, 6xHis-3, and
6xHis-4 extracts may indicate that residual pyruvate consuming machinery
maintains activity, but enzymes responsible for feeding PEP or cofactors into the
system begin to degrade125. Additionally, while the concentration of NAD+ is
bolstered by its exogenous addition during the reaction setup, the elimination of an
NADH sink, LdhA, may lead to decreased pooling of pyruvate at later timepoints7.
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These time-dependent changes may indicate that the glycolytic machinery
deteriorates faster than the remaining pyruvate degrading pathways. Alternatively,
the rapid consumption of the NAD+ supply could be limiting due to the potential
lack of cofactor recycling initiated by the removal of ldhA. Pyruvate consumption
experiments performed with the WT and 6xHis-4 lysates show that a significant
portion of the pyruvate consuming pathways remain robust after reduction
evidencing that the constraint may be due to bottlenecks in upstream glycolysis
(Appendix Figure 4.21).
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Figure 4.17. Comparisons of pyruvate concentration over time in WT, 6xHis-1, 6xHis-2, 6xHis-3,
and 6xHis-4 lysates. Data and standard deviation for the time course reactions were acquired using
n=3 biological replicates.

To validate the observed additive effects of successful LdhA and PpsA removals
on metabolic output, we generated a strain with a single 6xHis-ldhA insertion and
compared its extent of pyruvate pooling with the 6xHis-4-reduced lysates
(Appendix Figure 4.22). Importantly, the extract showed that while the reduction
of LdhA significantly impacts pyruvate accumulation, it was not solely responsible
for the effect. At its peak the 6xHis-ldhA reduced extract had only 15.73 mM
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pyruvate following reduction, falling significantly short of the 27.92 mM, 25.24 mM,
and 25.39 mM pyruvate values for 6xHis-2, 6xHis-3, 6xHis-4 mutants, respectively
(Figure 4.17 and Appendix Figure 4.22). This result highlights the importance of
using multiple 6xHis fusions as well as the potential need for developing cell-free
specific flux balance models for target selection.
To further understand the pyruvate pooling trends resulting from the use of
engineered lysates, differences between the unreduced and reduced proteomes
of each of the lysates were evaluated by mass spectrometry (Figure 4.18). As
expected for the WT extract, the reduction process did not significantly impact the
presence of the targeted proteins when comparing the peptide abundance values
of unreduced and reduced versions (Figure 4.18 A). On the other hand, a
substantial 3-to 4-fold decrease in relative LdhA abundance was evident in
reduced 6xHis-2, 6xHis-3, and 6xHis-4 lysates compared to their unreduced
counterparts (Figure 4.18 C, D, and E), which is consistent with the significant
increase in these extracts’ ability to accumulate pyruvate (Figure 4.16). PpsA was
also significantly pulled-down from only the 6xHis-3 and 6xHis-4 lysates.
Comparing the metabolic output of these lysates to that of the WT, we observed a
5- to 10-fold increase in pyruvate accumulation at earlier time points (Figure 4.17).
From the mass spectrometry-based proteomics profiling, it is evident that 6xHistagged LdhA and PpsA could be removed from lysates, while significant removal
of 6xHis-tagged PflB was not successful (Figure 4.18 B to E). Although the
decrease in PflB levels between the unreduced and reduced 6xHis-4 lysates met
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the significance threshold (pval < 0.05), the change was only a 1.81-fold reduction
compared to the significant decreases in LdhA and PpsA following lysate reduction
(Figure 4.18 E). AceE was not observed to be pulled down after the purification
of 6xHis-tagged proteins from the 6xHis-4 lysate. These findings are consistent
with metabolic output data in that the reduced 6xHis-1 and 6xHis-4 lysates seem
to pool as much pyruvate as the reduced WT and 6xHis-3 lysates, respectively
(Figure 4.17).
In their native context, such as in crude cell extracts, both PflB and AceE are
known to interact with other proteins. PflB binds to the cytoplasmic membrane
protein formate channel A, FocA, to facilitate the translocation of formate and this
strong association in E. coli lysates has been demonstrated by co-purification
experiments126.

AceE

is

the

pyruvate-binding

protein

of

the

pyruvate

dehydrogenase complex (PDHC), a stable multi-enzyme complex comprised of
two additional components, dihydrolipoyl transacetylase and dihydrolipoyl
dehydrogenase127. Individually, overexpressed PflB and AceE have been
successfully isolated from their interaction partners through 6xHis-tag purification
in the past. However, under native expression and structural context, the use of
6xHis-tags may not be effective for purifying complexed proteins as shorter tags
may not destabilize complexes117,126. We reason that the formation of these
protein-protein interactions may be restricting the accessibility of the target
proteins’ termini to the affinity resin, and therefore a larger protein tag that positions
itself outside of a complex may be a more favorable alternative 128. Alternatively,
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the 6xHis-tags of PflB and AceE are efficiently exposed to the resin, but binding is
sterically hindered by the large protein complexes. In this case, the application of
protein tags known to efficiently purify intact protein complexes may improve the
reduction method129.
We further analyzed proteomic changes in the unreduced and reduced extracts
to determine whether the reduction method resulted in the removal of off-target
proteins in reduced lysates. Importantly, the process of reducing the proteome did
not seem to significantly impact proteins in central metabolism outside of those
targeted by the reduction process. When comparing the reduced and unreduced
WT lysates, in the 58 proteins with a greater than 4-fold reduction, none were
connected to central metabolism outside of roles in membrane transport
(Supplemental Data 1). Future efforts will seek to minimize off-target effects by
using degradation instead of 6xHis tags in order to improve the general
applicability of lysate proteome engineering.
Targeted reduction of a lysate proteome enables a rapid means to manipulate
central metabolism without the possible drawback of cultivating “sick” organisms
as often results from traditional, in vivo metabolic engineering efforts. More
broadly, this new approach to engineering in vitro metabolism yields metabolic
states that are not traditionally possible in living organisms and sets important
groundwork for further developments in cell-free metabolic engineering
technology. The pORTMAGE system offers the potential for extension of this
engineering strategy to other, non-model cell-free chassis. Future improvements
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to lysate proteome engineering could also entail the use of multiplex genome
engineering methods that are amenable to the insertion of larger tags 120,130,131. To
further advance the reduction of the lysate’s proteome, orthogonal protein
degradation systems could be employed wherein proteins are genomically tagged
and degraded in a cell-free extract using an exogenous protease. The mf-lon
protease system serves this function. This protease targets a 27 amino acid long
peptide

and

may

overcome

issues

associated

with

targeting

protein

complexes132,133.

Figure 4.18. Proteomic analysis of an unreduced cell-free extract (blue), and a reduced cell-free
extract (orange). Significant fold-changes in protein concentration when comparing the reduced to
the unreduced extract are denoted by p-value and fold change reduction in concentration of the
protein above a bracket. Panels A, B, C, D, and E denote the WT, 6xHis-1, 6xHis-2, 6xHis-3, and
D. 6xHis-4 strains, respectively. Asterisks indicate proteins targeted for removal in the reduced
strain.
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Methods
Generation and Validation of Genome Engineered Strains using MAGE
All Multiplex allele-specific PCR (MASC-PCR), Sanger Sequencing oligos, and
recombineering oligos were created manually and ordered from IDT with standard
purification. Each targeting oligo incorporated four phosphorothioated bases on
the 5′ terminus. An 18-base CACCATCACCATCACCAT sequence was used to
add the His-tag and directed at either the N- or C-terminus based on previous
literature or crystal structure analysis117,118. The pORTMAGE protocol used in this
study followed previous work with the exception that growth was carried out in 6
mL of Luria-Bertani-Lennox (lbl) cultures in glass tubes with 100 mg/mL of
carbenicillin, recovery was performed in 3 mL of terrific broth with a 1-hour
incubation time prior to adding 3 mL of lbl-carb for outgrowth134. Given the
significant time required to find accumulated mutations in a single strain, the
additive mutations were started from previously found mutations such that Δ1 was
used to create Δ2 and so on as per the protocols used in previous studies 109. After
every 8-12 cycles of MAGE, 30-60 colonies were screened for genome edits using
MASC-PCR as detailed previously. Allelic genotyping was performed using
standard primers designed to flank both modified genes. Amplicons were Sanger
sequenced to validate the insertion of the His-tag sequence. Primer sequences
used in this study are listed in (Appendix Table 4.8) and (Appendix Table 4.9).
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Cell-Free Extract Preparation Protocol
Following plasmid curing, the cell extracts were prepared from E. coli BL21 Star
(DE3) grown at 37 °C in 2xYPTG (16 g L-1 tryptone, 10 g L-1 yeast extract, 5 g L1 NaCl, 7 g L-1 KH2PO4, 3 g L-1 K2HPO4, 18 g L -1 glucose). Cell extracts were
prepared by harvesting 50-mL cultures grown in baffled Erlenmeyer flasks to an
OD600 of 4.5 Cells were harvested by centrifugation at 5000x g for 10 min in 50
mL volumes and washed twice with S30 buffer (14 mM magnesium acetate, 60
mM potassium glutamate, 1 mM dithiothreitol (DTT) and 10 mM Tris-acetate, pH
8.2) by resuspension and centrifugation. The pellets were weighed, flash-frozen
and stored at –80 °C. Extracts were prepared by thawing and resuspending the
cells in 0.8 mL of S30 buffer per mg of cell wet weight. The resuspension was lysed
using 530 joules per mL of suspension at 50% tip amplitude with ice water cooling.
Following sonication, tubes of cell extract were centrifuged twice at 21,100 x g for
10 minutes at 4 °C, aliquoted, frozen with liquid nitrogen, and stored at –80 °C.
Cell-Free Extract Reductions
Cell extracts were reduced by adding one volume of cell extract to 0.2X volume
of ice-cold HisPur™ Cobalt Resin (ThermoFisher Scientific) suspension in 1.5 mL
microcentrifuge tubes. Prior to the addition of lysate, HisPur™ Cobalt Resin was
washed 2X with 500 µL S30 buffer and incubated with 10 mM imidazole buffer (pH
4.5; 10 mM imidazole, 50 mM monopotassium chloride, 300 mM NaCl). Lysateresin mixtures were incubated for 1 hour at 4˚C under shaking conditions (800 rpm)
to ensure the suspension of the resin particles in the extracts then centrifuged at
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14,000 x g for 30 seconds. Supernatants were aliquoted, flash-frozen, and stored
at -80˚C until used. His-tagged proteins were eluted from the HisPur™ Cobalt
Resin by suspending the resin in 50 µL elution buffer (pH 4.5; 250 mM Imidazole,
50 mM monosodium phosphate, 300 mM NaCl) for 30 minutes at 4˚C under
shaking conditions (800 rpm). The eluate was obtained for proteomic quantification
by spinning down the suspension at 14,000 x g for 30 seconds and collecting the
supernatant.
CFME Reaction Set-up
Glucose consumption reactions were carried out at 37 °C in 50 μL volumes
using a solution of 250 mM glucose, 18 mM magnesium glutamate, 15 mM
ammonium glutamate, 195 mM potassium glutamate, 1 mM ATP, 150 mM BisTris, 1 mM NAD+, 10 mM dipotassium phosphate. Similarly, pyruvate fed reactions
were carried out using the conditions with the exception of 25 mM pyruvate being
used in place of glucose. Extracts were added to a final protein concentration of
4.5 mg mL-1. Each reaction was quenched by the addition of 50 μL of 5% TCA.
The supernatant was centrifuged at 11,000 x g for 5 minutes and directly used for
analytical measurements.
Proteomics Sample Preparation
Cell extracts were solubilized in 200 μL of 4% SDS in 100 mM Tris buffer, pH
8.0. Trichloroacetic acid was added to achieve a concentration of 20% (wt/vol).
Samples were vortexed and incubated at 4C for 2 h followed by 10 min at -80C.
Samples were then thawed on ice prior to centrifugation (~21,000g) for 10 min at
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4C to pellet precipitated proteins from the detergent and solutes. The supernatant
was discarded, and samples were washed with 1 mL of ice-cold acetone. Pelleted
proteins were then air-dried and resuspended in 100 μL of 8 M urea in 100 mM
Tris buffer, pH 8.0. Proteins were reduced with 10mM dithiothreitol incubated for
30 min and alkylated with 30mM iodoacetamide for 15 min in dark at room
temperature. Proteins were digested with two separate and sequential aliquots of
sequencing grade trypsin (Promega) of 1 μg. As 8 M urea inhibits trypsin, samples
were diluted to 4 M urea for a 3 hours digestion, followed by dilution to 2 M urea
for overnight digestion. Samples were then adjusted to 0.1% trifluoroacetic acid
and then desalted on Pierce peptide desalting spin columns (Thermo Scientific) as
per the manufacturer instructions. Samples were vacuum-dried with a SpeedVac
(Thermo Scientific) and then resuspended in 50 μL of 0.1% formic acid. Peptide
concentrations were then measured using nanodrop (Thermo Scientific) and 2 μg
of each sample was used for LC-MS measurement.
LC-MS/MS analysis
All samples were analyzed on a Q Exactive Plus mass spectrometer (Thermo
Scientific) coupled with an automated Vanquish UHPLC system (Thermo
Scientific). Peptides were separated on a triphasic precolumn (RP-SCX-RP; 100
μm inner diameter and 15 cm total length) coupled to an in-house-pulled
nanospray emitter of 75 μm inner diameter packed with 25 cm of 1.7 μm of Kinetex
C18 resin (Phenomenex). For each sample, a single 2μg injection of peptides was
loaded and analyzed across a salt cut of ammonium acetate (500mM) followed by
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a 210 min split-flow (300nL/min) organic gradient, wash, and re-equilibration: 0%
to 2% solvent B over 27 min, 2% to 25% solvent B over 148 min, 25% to 50%
solvent B over 10 min, 50% to 0% solvent B over 10 min, hold at 0% solvent B for
15 min. MS data were acquired with the Thermo Xcalibur software using the top
10 data-dependent acquisition.
Proteome Database Search
All MS/MS spectra collected were processed in Proteome Discoverer, version
2.3 with MS Amanda and Percolator. Spectral data were searched against the
most recent E. coli reference proteome database from UniProt to which mutated
sequences and common laboratory contaminants were appended. The following
parameters were set up in MS Amanda to derive fully tryptic peptides: MS1
tolerance = 5 ppm; MS2 tolerance = 0.02 Da; missed cleavages = 2;
Carbamidomethyl (C, + 57.021 Da) as static modification; and oxidation (M, +
15.995 Da) as dynamic modifications. The Percolator FDR threshold was set to
1% at the peptide-spectrum match and peptide levels. FDR-controlled peptides
were then quantified according to the chromatographic area-under-the-curve and
mapped to their respective proteins. Areas were summed to estimate protein-level
abundance.
Proteomic Data Analysis
For differential abundance analysis of proteins, the protein table was exported
from Proteome Discoverer. Proteins were filtered to remove stochastic sampling.
All proteins present in 2 out of 3 biological replicates in any condition were
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considered valid for quantitative analysis. Data was log 2 transformed, LOESS
normalized between the biological replicates and mean-centered across all the
conditions. Missing data were imputed by random numbers drawn from a normal
distribution (width = 0.3 and downshift = 2.8 using Perseus software
(http://www.perseus-framework.org). The resulting matrix was subjected to
ANOVA and a post-hoc TukeyHSD test to assess protein abundance differences
between the different experimental groups. The statistical analyses were done
using an in-house developed R script.
Glucose and pyruvate measurements
Pyruvate and glucose measurements were performed using high-performance
liquid chromatography (HPLC). An Agilent 1260 equipped with an Aminex HPX 87H column (Bio-Rad, Hercules, CA) and a diode array UV-visible detector (Agilent,
Santa Clara, CA) reading at 191 nm. Analytes were eluted with isocratic 5 mM
sulfuric acid at a flow rate of 0.55 mL min–1 at 35 °C for 25 min. Pyruvate and
glucose standards were used for sample quantification using linear interpolation of
external standard curves.
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Conclusion
Shown in this work was the use of genome engineering to affect in vivo protein
modifications that lead to directed metabolic activity in the derived lysates. This
novel cell-free metabolic engineering strategy allows targeted removal of
enzymes, thus enabling the production of metabolites from simple precursors
using rapidly prepared crude extracts135–138. The ability to extract pyruvate
degrading enzymes, leading to unconventional metabolic states, was engineered
and shown to be capable of pooling pyruvate for a significant period of time. The
ability to direct metabolic flux in cell-free systems and create proteomes untenable
to living cells was demonstrated. The flexibility of CFME systems highlights the
significant value they hold as novel bioproduction platforms. The advances made
in this work can be extended to design molecule specific donor strains for natural
product biosynthesis, such as for polyketides or carbohydrates, through the
removal of defined inhibitory reactions. The ability to reduce specific components
of crude lysates allows for more complex reaction networks to be employed in the
development of CFME bioproduction platforms. As CFME begins to tackle new
challenges related to antibiotic, fuel, and materials production, innovative
engineering tools and techniques will be crucial to advancing the scope and
adoption of cell-free biological production.
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Table 4.8. MAGE oligos use for this study. Phosphorothioated bases are noted with asterisks.
Primer
Sequence
Pfl
a*a*t*a*aaaaatccacttaagaaggtaggtgttacatgCACcatCACcatCACCATtccgagcttaatga
aaagttagccacagcctgggaa
Ldh
t*a*a*a*tgtgattcaacatcactggagaaagtcttatgCACcatCACcatCACCATaaactcgccgtttata
gcacaaaacagtacgacaag
Ppsa
c*a*a*a*ccgttcatttatcacaaaaggattgttcgatgCACcatCACcatCACCATtccaacaatggctcgt
caccgctggtgctttggtat
Pdh
a*c*t*c*aacgttattagatagataaggaataacccatgCACcatCACcatCACCATtcagaacgtttccc
aaatgacgtggatccgatcgaa

Table 4.9. MASC-PCR oligos used for this study.
Primer
Sequence
Pfl F
GCCAGCCAGGAAGGACTCGTCACCCTCG
Pfl R
GCAGTAAATAAAAAATCCACTTAAGAAGGTAGGTGTTACATGC
Ldh F
CAGCGTCATCATCATACCGATGGC
Ldh R
CTTAAATGTGATTCAACATCACTGGAGAAAGTCTTATGC
Ppsa F
GCTGGTTTACGCCGCTTTGGTCC
Ppsa R
ACCGTTCATTTATCACAAAAGGATTGTTCGATGC
Pdh F
TGGCCTTTATCGAAGAAATTTTGCTCGACAG
Pdh R
ATCCACGTCATTTGGGAAACGTTCTGAA
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Figure 4.19. Growth rate and terminal OD600 was measured using for the four main strains
produced for this study.
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Figure 4.20. Glucose measured over a 24-hour time period.
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Figure 4.21. Comparison of pyruvate concentration changes when fed 100 mM glucose for an
extract with a single reduction of ldhA to an extract reduced for all 4 proteins his-ldhA, his-pflB, hisppsa, his-aceE.
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conditions were exactly as those used for the glucose consuming reactions aside from the
replacement of glucose with 25 mM pyruvate.
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Conclusions
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Since their inception, cell-free systems have found uses as powerful research
tools in a variety of applications due to their ability to emulate a living system. What
once helped decipher the genetic code is now being applied to biological
production, protein characterization, and the development of synthetic cells139. As
the challenges of synthetic biology and biological research continue to expand, so
too will the technology of cell-free systems need to develop in order to keep pace
and fulfill future needs. The work presented in this dissertation provides tools and
applications to expand the use of cell-free systems to showcase their application
towards solving complex biological problems.
Specifically, this work focus on the development of cell-free systems as conduits
for the exploration of cellular metabolism and in vitro biological production from
microorganisms. Due to the advent of next-generation sequencing and genome
mining techniques, our continuously expanding repositories of biological
information have been left with few tools for rapid and empirical verification. These
datasets contain significant amounts of information regarding the function, stability,
and metabolic output of the microbial world. Whereas traditional in vivo systems
can be limited by cytotoxicity and the metabolic burdens of living cells, cell-free
systems are only limited by an understanding of their chemical processes. The
scalable nature of cell-free systems present an excellent opportunity to both
elucidate the function of microbial dark matter through pathway identification and
to harness the metabolic potential of microbial organisms through cell-free
metabolic engineering.
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To the ends described above, I published three papers, presented here as
chapters, exploring uncharacterized metabolic pathways, analyzing the effects of
growth conditions on extracts, and developing tools to engineer cell-free
metabolism25,30,140. A key aspect of these projects is the role they share in taking
cell-free biology and further expanding our understanding of its capabilities to
facilitate its use. Each work, therefore, reflects an improved understanding of the
role of cell-free systems as research and industrial tools.
Chapter one attempted to express metabolic pathways outside of their native
context to showcase the utility of crude cell-free extracts as a verification tool for
computationally predicated metabolic pathways. These efforts allowed us to
elucidate the metabolic pathways used by Pantoea sp. YR 343 to produce IAA.
The key feature of our approach is the combination of computational and empirical
tools to both rapidly predict and verify the activity of a given pathway. This platform
ultimately allowed us to show that Pantoea sp. YR 343 was capable of using
multiple enzymatic combinations to produce IAA. The insights learned allows for
more conventional tools such as genome and metabolic engineering to be used
without a significant fear of wasted resources and time.
Chapter two seeks to improve pyruvate production in cell-free systems, by
measuring the impacts modifications to media and preparation conditions can have
on protein content and showed how these changes can be leveraged to improve
biosynthetic processes in vitro. The effects of four growth conditions for a crude
S30 E. coli lysate were assessed with shotgun proteomics and analytical
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measurements. Our use of proteomic techniques helped to validate the metabolic
measurements made from CFME reactions. Ultimately, we showed that the
proteome of a cell-free extract can have a significant impact on the performance
and function of a cell-free extract as each extract both pooled and consumed
pyruvate at significantly different levels. These experiments furthered our interest
in CFME as the Y-TE extract while being capable of pooling a large amount of
pyruvate was not doing so in stoichiometric quantities. This indicated that a
significant portion of our feeding substrate was being consumed by side reactions.
A problem that would need to be solved before CFME systems could have a
significant impact as bioproduction platforms.
Chapter three sought to help resolve some of the problems associated with
CFME by designing a cell-free specific genome engineering system. While
traditional tools would simply remove proteins deleterious to the production of a
specific metabolite and thereby risk a cytotoxic phenotype, the system we
designed for this work alleviated this concern by performing the deletion process
after lysis. Reducing the cell-free proteome enables complex reaction networks to
be modified for the development of CFME. We successfully engineered an
unconventional metabolism able to produce pyruvate and showed an important
proof of principle for creating proteomes untenable to living cells.
Future efforts will seek to expand the throughput and efficiency of the work
described in this dissertation. While ligand docking using Autodock Vina is useful
for rapidly predicting protein function, more powerful computational tools such a
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molecular dynamics, though slow outside of large computational clusters, would
significantly improve the accuracy of the protein-ligand interactions. The use of
liquid handling systems could also significantly increase the rate at which predicted
enzymes could be tested and pathways verified. One problem seen in the
development of our reduced cell-free metabolic engineering extracts was the
incomplete degradation of the tagged proteins. A promising avenue for a more
complete reduction is the use of an orthogonal protein degradation system such
as that of the mf-Lon protease. Instead of removing the proteins from the extract,
degradation tags would be introduced into target proteins and degraded after lysis
of the cell133. Though at the moment, such large tags can only be added in
multiplex to organisms with natural competence like Vibrio natriegens, the process
could also be replicated in E. coli as advances to MAGE are released.
Cell-free systems derive their function from a complex set of biochemistries
removed from the context of cellular regulation. Free from membranes and
endogenous genetic material, the relatively static proteome becomes open to more
dramatic changes to its environment. This enables cell-free systems to elucidate
the functions of complex chemical networks or generate molecules using
unconventional metabolic states. As the need for scalable biological tools
continues to expand, these characteristics will further incentivize the study and use
of cell-free systems. Continuing to develop these powerful tools will enable
scientists and engineers to create novel biological production platforms cheaply
and sustainably.
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